WO2020163480A1 - Alpha-glucosidase acide humaine recombinée et utilisations associées - Google Patents

Alpha-glucosidase acide humaine recombinée et utilisations associées Download PDF

Info

Publication number
WO2020163480A1
WO2020163480A1 PCT/US2020/016794 US2020016794W WO2020163480A1 WO 2020163480 A1 WO2020163480 A1 WO 2020163480A1 US 2020016794 W US2020016794 W US 2020016794W WO 2020163480 A1 WO2020163480 A1 WO 2020163480A1
Authority
WO
WIPO (PCT)
Prior art keywords
subject
months
score
treatment
rhgaa
Prior art date
Application number
PCT/US2020/016794
Other languages
English (en)
Inventor
Hung Do
Russell GOTSCHALL
Hing CHAR
Jay Barth
Sheela Sitaraman
Hjalmar Lagast
Original Assignee
Amicus Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics, Inc. filed Critical Amicus Therapeutics, Inc.
Publication of WO2020163480A1 publication Critical patent/WO2020163480A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)

Definitions

  • the present invention involves the fields of medicine, genetics and recombinant glycoprotein biochemistry, and, specifically, relates to recombinant human a-glucosidase (rhGAA) compositions that have a higher total content of mannose -6-phosphate-bearing N-glycans that efficiently target CIMPR on cells and subsequently deliver rhGAA to the lysosomes where it can break down abnormally high levels of accumulated glycogen.
  • the rhGAA of the invention exhibits superior uptake into muscle cells and subsequent delivery to lysosomes compared to conventional rhGAA products and exhibits other pharmacokinetic properties that make it particularly effective for enzyme replacement therapy of subjects having Pompe disease.
  • the present invention also provides a method for treating Pompe disease comprising administering to an individual a combination of an rhGAA and a pharmacological chaperone.
  • the present invention provides a method for treating Pompe disease comprising administering to an individual a combination of rhGAA and miglustat.
  • the rhGAA of the invention exhibits surprising efficacy in treating and reversing disease progression in subjects suffering from Pompe disease.
  • Pompe disease is an inherited lysosomal storage disease that results from a deficiency in acid a-glucosidase (GAA) activity.
  • a person having Pompe Disease lacks or has reduced levels of acid a-glucosidase (GAA), the enzyme which breaks down glycogen to glucose, a main energy source for muscles.
  • GAA acid a-glucosidase
  • This enzyme deficiency causes excess glycogen accumulation in the lysosomes, which are intra-cellular organelles containing enzymes that ordinarily break down glycogen and other cellular debris or waste products. Glycogen accumulation in certain tissues of a subject having Pompe Disease, especially muscles, impairs the ability of cells to function normally.
  • Pompe Disease glycogen is not properly metabolized and progressively accumulates in the lysosomes, especially in skeletal muscle cells and, in the infant onset form of the disease, in cardiac muscle cells. The accumulation of glycogen damages the muscle and nerve cells as well as those in other affected tissues. [005] Traditionally, depending on the age of onset, Pompe disease is clinically recognized as either an early infantile form or as a late onset form. The age of onset tends to parallel the severity of the genetic mutation causing Pompe Disease. The most severe genetic mutations cause complete loss of GAA activity and manifest as early onset disease during infancy. Genetic mutations that diminish GAA activity but do not eliminate it are associated with forms of Pompe disease having delayed onset and progression.
  • Infantile onset Pompe disease manifests shortly after birth and is characterized by muscular weakness, respiratory insufficiency and cardiac failure. Untreated, it is usually fatal within two years. Juvenile and adult onset Pompe disease manifest later in life and usually progress more slowly than infantile onset disease. This form of the disease, while it generally does not affect the heart, may also result in death, due to weakening of skeletal muscles and those involved in respiration.
  • ERT enzyme replacement therapy
  • rhGAA recombinant human GAA
  • This conventional enzyme replacement therapy seeks to treat Pompe Disease by replacing the missing GAA in lysosomes by administering rhGAA thus restoring the ability of cells to break down lysosomal glycogen.
  • “Lumizyme®” and“Myozyme®” are conventional forms of rhGAA produced or marketed as biologies by Genzyme and approved by the U.S. Food and Drug Administration, and are described by reference to the Physician's Desk Reference (2014) (which is hereby incorporated by reference).
  • Alglucosidase alfa is identified as chemical name [199-arginine, 223-histidine]prepro-a-glucosidase (human); molecular formula, C4758H7262N1274O1369S35; CAS number 420794-05-0. These products are administered to subjects with Pompe Disease, also known as glycogen storage disease type II (GSD-II) or acid maltase deficiency disease.
  • Pompe Disease also known as glycogen storage disease type II (GSD-II) or acid maltase deficiency disease.
  • rhGAA cation-independent mannose-6- phosphate receptor
  • rhGAA products at 20 mg/kg or higher doses do ameliorate some aspects of Pompe disease, they are not able to adequately, among other things, (i) treat the underlying cellular dysfunction, (ii) restore muscle structure, or (iii) reduce accumulated glycogen in many target tissues, such as skeletal muscles, to reverse disease progression. Further, higher doses may impose additional burdens on the subject as well as medical professionals treating the subject, such as lengthening the infusion time needed to administer rhGAA intravenously. There remains a need for further improvements to enzyme replacement therapy for treatment of Pompe disease, such as rhGAA with improved tissue uptake, improved enzymatic activity, improved stability, or reduced immunogenicity.
  • the glycosylation of GAA or rhGAA can be enzymatically modified in vitro by the phosphotransferase and uncovering enzymes described by Canfield, et al., U.S. Patent No. 6,534,300, to generate M6P groups.
  • Enzymatic glycosylation cannot be adequately controlled and can produce rhGAA having undesirable immunological and pharmacological properties.
  • Enzymatically modified rhGAA may contain only high-mannose oligosaccharide which all could be potentially enzymatically phosphorylated in vitro with a phosphotransferase or uncovering enzyme and may contain on average 5-6 M6P groups per GAA.
  • glycosylation patterns produced by in vitro enzymatic treatment of GAA are problematic because the additional terminal mannose residues, particularly non- phosphorylated terminal mannose residues, negatively affect the pharmacokinetics of the modified rhGAA.
  • these mannose groups increase non-productive clearance of the GAA, increase the uptake of the enzymatically- modified GAA by immune cells, and reduce rhGAA therapeutic efficacy due to less of the GAA reaching targeted tissues, such as skeletal muscle myocytes.
  • terminal non- phosphorylated mannose residues are known ligands for mannose receptors in the liver and spleen which leads to rapid clearance of the enzymatically-modified rhGAA and reduced targeting of rhGAA to target tissue.
  • the glycosylation pattern of enzymatically -modified GAA having high mannose N-glycans with terminal non-phosphorylated mannose residues resembles that on glycoproteins produced in yeasts and molds, and increases the risk of triggering immune or allergic responses, such as life-threatening severe allergic (anaphylactic) or hypersensitivity reactions, to the enzymatically modified rhGAA.
  • the inventors also report that the rhGAA of the present invention reverses the disease progression—including clearing lysosomal glycogen more efficiently than the current standard of care— and that patients treated with the rhGAA of the present invention exhibit surprising and significant health improvements, including improvements in muscle strength, motor function, and/or pulmonary function, and/or including a reversal in disease progression, as demonstrated in various efficacy results (e.g., Examples 10 and 11) from the clinical studies.
  • the present invention relates to a method of treating a disease or disorder such as Pompe disease in a subject, comprising administering a population of recombinant human acid a- glucosidase (rhGAA) molecules.
  • a disease or disorder such as Pompe disease
  • rhGAA recombinant human acid a- glucosidase
  • the rhGAA molecules described herein may be expressed in Chinese hamster ovary (CHO) cells and comprise seven potential N-glycosylation sites.
  • the N- glycosylation profde of a population of rhGAA molecules as described herein is determined using liquid chromatography -tandem mass spectrometry (LC -MS/MS).
  • the rhGAA molecules on average comprise 3-4 mannose-6-phosphate (M6P) residues.
  • the rhGAA molecules on average comprise about at least 0.5 mol bis-phosphorylated N-glycan groups (bis-M6P) per mol of rhGAA at the first potential N-glycosylation site.
  • the rhGAA comprises an amino acid sequence at least 95% identical to SEQ ID NO: 4 or SEQ ID NO: 6. In some embodiments, the rhGAA comprises an amino acid sequence identical to SEQ ID NO: 4 or SEQ ID NO: 6. In some embodiments, at least 30% of molecules of the rhGAA molecules comprise one or more N-glycan units bearing one or two M6P residues. In some embodiments, the rhGAA molecules comprise on average from about 0.5 mol to about 7.0 mol of N-glycan units bearing one or two M6P residues per mol of rhGAA.
  • the rhGAA molecules comprises on average at least 2.5 moles of M6P residues per mol of rhGAA and at least 4 mol of sialic acid residues per mol of rhGAA.
  • the rhGAA molecules comprising an average of 3-4 M6P residues per molecule and an average of about at least 0.5 mol bis-M6P per mol rhGAA at the first potential N-glycosylation site further comprise an average of about 0.4 to about 0.6 mol mono- phosphorylated N-glycans (mono-M6P) per mol rhGAA at the second potential N-glycosylation site, about 0.4 to about 0.6 mol bis-M6P per mol rhGAA at the fourth potential N-glycosylation site, and about 0.3 to about 0.4 mol mono-M6P per mol rhGAA at the fourth potential N-glycosylation site.
  • the rhGAA molecules further comprise on average about 4 mol to about 7.3 mol of sialic acid residues per mol of rhGAA, including about 0.9 to about 1.2 mol sialic acid per mol rhGAA at the third potential N-glycosylation site, about 0.8 to about 0.9 mol sialic acid per mol rhGAA at the fifth potential N-glycosylation site, and about 1.5 to about 4.2 mol sialic acid per mol rhGAA at the sixth potential N-glycosylation site.
  • the population of rhGAA molecules is formulated in a pharmaceutical composition.
  • the pharmaceutical composition comprising a population of rhGAA molecules further comprises at least one buffer selected from the group consisting of a citrate, a phosphate, and a combination thereof, and at least one excipient selected from the group consisting of mannitol, polysorbate 80, and a combination thereof.
  • the pH of the pharmaceutical composition is about 5.0 to about 7.0, about 5.0 to about 6.0, or about 6.0.
  • the pharmaceutical composition further comprises water, an acidifying agent, an alkalizing agent, or a combination thereof.
  • the pharmaceutical composition has a pH of 6.0 and comprises about 5-50 mg/mL of the population of rhGAA molecules, about 10-100 mM of a sodium citrate buffer, about 10-50 mg/mL mannitol, about 0.1-1 mg/mL polysorbate 80, and water, and optionally comprises an acidifying agent and/or alkalizing agent.
  • the pharmaceutical composition has a pH of 6.0 and comprises about 15 mg/mL of the population of rhGAA molecules, about 25 mM of a sodium citrate buffer, about 20 mg/mL mannitol, about 0.5 mg/mL polysorbate 80, and water, and optionally comprises an acidifying agent and/or alkalizing agent.
  • the population of rhGAA molecules is administered at a dose of about 1 mg/kg to about 100 mg/kg or about 5 mg/kg to about 20 mg/kg. In some embodiments, the population of rhGAA molecules is administered at a dose of about 20 mg/kg. In some embodiments, the population of rhGAA molecules is administered bimonthly, monthly, bi-weekly, weekly, twice weekly, or daily, for example, bi-weekly. In some embodiments, the population of rhGAA molecules is administered intravenously.
  • the population of rhGAA molecules is administered concurrently or sequentially with a pharmacological chaperone such as miglustat (also referred to as AT2221) or a pharmaceutically acceptable salt thereof.
  • a pharmacological chaperone such as miglustat (also referred to as AT2221) or a pharmaceutically acceptable salt thereof.
  • the miglustat or pharmaceutically acceptable salt thereof is administered orally, for example at a dose of about 50 mg to about 200 mg or from about 200 mg to about 600 mg, and optionally about 130 mg or about 260 mg.
  • the population of rhGAA molecules is administered intravenously at a dose of about 5 mg/kg to about 20 mg/kg and the miglustat or pharmaceutically acceptable salt thereof is administered orally at a dose of about 233 mg to about 500 mg.
  • the the population of rhGAA molecules is administered intravenously at a dose of about 5 mg/kg to about 20 mg/kg and the miglustat or pharmaceutically acceptable salt thereof is administered orally at a dose of about 50 mg to about 200 mg. In one embodiment, the population of rhGAA molecules is administered intravenously at a dose of about 20 mg/kg and the miglustat or pharmaceutically acceptable salt thereof is administered orally at a dose of about 260 mg. In some embodiments, the miglustat or pharmaceutically acceptable salt thereof is administered prior to (for example, about one hour prior to) administration of the population of rhGAA molecules. In at least one embodiment, the subject fasts for at least two hours before and at least two hours after the administration of miglustat or a pharmaceutically acceptable salt thereof.
  • Embodiments of the invention demonstrate the efficacy of the rhGAA described herein to treat and reverse disease progression in a subject with Pompe disease.
  • the population of rhGAA molecules is administered at a dosage capable of reducing glycogen content in a muscle of the subject faster than the same dosage of alglucosidase alfa.
  • the rhGAA may reduce glycogen content at least about 1.25, 1.5, 1.75, 2.0, or 3.0 times faster than the same dosage of alglucosidase alfa.
  • the population of rhGAA molecules is administered at a dosage further capable of reducing glycogen content in a muscle of the subject more effectively than alglucosidase alfa administered at the same dosage when assessed after one, two, three, four, five, or six administrations.
  • the population of rhGAA molecules reduces glycogen content at least about 10%, 20%, 30%, 50%, 75%, or 90% more effectively than does alglucosidase alfa administered at the same dosage.
  • the population of rhGAA molecules is administered at a dosage capable of reducing levels of urine hexose tetrasaccharide (Hex4), e.g. at 21 months or 24 months after treatment.
  • Hex4 levels in the subject are reduced by at least 30% at 21 months or 24 months after treatment relative to baseline.
  • an ambulatory subject previously treated with enzyme replacement therapy an ambulatory ERT-switch patient
  • an ambulatory subject who has not previously received enzyme replacement therapy an ambulatory ERT-nafve patient
  • the population of rhGAA molecules is administered at a dosage capable of improving motor function in the subject, e.g., at 21 months or 24 months after treatment. Improvement in motor function may be measured by a motor function test such as a six- minute walk test (6MWT), a timed up and go test, a four-stair climb test, a ten-meter walk test, a gowers test, a gait-stair-gower-chair (GSGC) test, or a combination thereof.
  • 6MWT six- minute walk test
  • a timed up and go test e.g., a timed up and go test
  • a four-stair climb test e.g., a four-stair climb test
  • a ten-meter walk test e.g., a gowers test
  • GSGC gait-stair-gower-chair
  • the subject 21 or 24 months after treatment shows a 6MWT distance increase of at least 50 meters, a timed up and go test time decrease of at least 1 second, and/or a GCSC score decrease of at least 1.
  • an ambulatory ERT-switch patient, 24 months after treatment (compared to baseline) may exhibit a 6MWT increase of at least 50 meters, a timed up and go test time decrease of at least 1.2 seconds, and/or a GSGC score decrease of at least 1.6 seconds.
  • an ambulatory ERT-nafve patient 21 months after treatment (compared to baseline), may exhibit a 6MWT distance increase of at least 50 meters, a timed up and go test time decrease of at least 0.7 seconds, and/or a GSGC score decrease of at least 1.8.
  • an ERT- switch patient exhibits an improvement in at least one motor function test after treatment relative to the patient’s motor function test result after a previous ERT with alglucosidase alfa.
  • the population of rhGAA molecules is administered at a dosage capable of improving upper body strength or total body strength in the subject.
  • the improvement in upper body strength is measuring using a manual muscle strength score.
  • a subject’s manual muscle strength score may improve by at least 2.5 for an ambulatory ERT-switch patient at 24 months after treatment relative to baseline or may improve by at least 1 for a nonambulatory ERT-switch patient or ambulatory ERT-nafve patient at 21 months after treatment relative to baseline.
  • an ERT-switch patient exhibits an improvement in upper body strength after treatment relative to the patient’s upper body strength after a previous ERT with alglucosidase alfa.
  • the population of rhGAA molecules is administered at a dosage capable of improving pulmonary function in the subject, e.g., at 21 months or 24 months after treatment. Improvement in motor function may be measured by a pulmonary function test such as an upright (sitting) forced vital capacity test, a a maximal expiratory pressure (MEP) test, a maximal inspiratory pressure (MIP) test, or a combination thereof.
  • a pulmonary function test such as an upright (sitting) forced vital capacity test, a a maximal expiratory pressure (MEP) test, a maximal inspiratory pressure (MIP) test, or a combination thereof.
  • the subject 21 or 24 months after treatment shows an improvement in FVC of at least 6%, an improvement in MEP of at least 12 cmEhO, and/or an improvement in MIP of at least 7 cmEhO.
  • an ambulatory ERT-switch patient 24 months after treatment (compared to baseline), may exhibit an improvement in MEP of at least 26 cmEbO.
  • an ambulatory ERT-nafve patient, 21 months after treatment (compared to baseline) may exhibit an improvement in FVC of at least 6%, an improvement in MIP of at least 7 cmEbO, and/or an improvement in MEP of at least 12 cmEbO.
  • an ERT-switch patient exhibits an improvement in at least one pulmonary function test after treatment relative to the patient’s pulmonary function test result after a previous ERT with alglucosidase alfa.
  • the population of rhGAA molecules is administered at a dosage capable of improving patient-reported outcome as determined by Rasch-built Pompe-specific activity (R-PAct) score, Rotterdam Handicap Scale score, Fatigue Severity Scale (FSS) score, and/or Subject Global Impression of Change (SGIC) score.
  • R-PAct Rasch-built Pompe-specific activity
  • FSS Fatigue Severity Scale
  • SGIC Subject Global Impression of Change
  • the population of rhGAA is administered at a dosage capable of improving a patient-reported outcome as determined by R-PAct score at six, 12, 21, or 24 months after treatment compared to baseline.
  • the subject’s R-PAct score at six months after treatment is increased by at least 1.5 compared to baseline .
  • the subj ect’ s R-PAct score at 12 months after treatment is increased by at least 1.0 compared to baseline.
  • the subject’s R-PAct score at 21 months or 24 months after treatment is increased by at least 1.0 compared to baseline.
  • the subject is an ambulatory ERT-switch patient and the subject’s R-PAct score at six months after treatment is increased by at least 1.0 compared to baseline, the subject’s R-PAct score at 12 months after treatment is increased by at least 1.0 compared to baseline, or the subject’s R-PAct score at 24 months after treatment is increased by at least 1.0 compared to baseline, or a combination thereof.
  • the subject is an ambulatory ERT-switch patient and the subject’s R-PAct score at six months after treatment is increased by at least 1.5 compared to baseline, or the subject’s R-PAct score at 12 months after treatment is increased by at least 1.5 compared to baseline, or a combination thereof.
  • the subject is an ambulatory ERT-switch patient and the subject’s R-PAct score at six months after treatment is increased by at about 1.5 compared to baseline, the subject’s R-PAct score at 12 months after treatment is increased by about 1.7 compared to baseline, or the subject’s R-PAct score at 24 months after treatment is increased by about 1.4 compared to baseline, or a combination thereof.
  • the subject is a nonambulatory ERT-switch patient and the subject’s R-PAct score at six months after treatment is increased by at least 1.0 compared to baseline, the subject’s R-PAct score at 12 months after treatment is increased by at least 1.0 compared to baseline, or the subject’s R-PAct score at 21 months after treatment is increased by at least 1.0 compared to baseline, or a combination thereof.
  • the subject is a
  • nonambulatory ERT-switch patient and the subject’s R-PAct score at six months after treatment is increased by at least 1.5 compared to baseline, or the subject’s R-PAct score at 21 months after treatment is increased by at least 1.5 compared to baseline, or a combination thereof.
  • the subject is a nonambulatory ERT-switch patient and the subject’s R-PAct score at six months after treatment is increased by at about 1.5 compared to baseline, the subject’s R-PAct score at 12 months after treatment is increased by about 1.0 compared to baseline, or the subject’s R- PAct score at 21 months after treatment is increased by about 1.5 compared to baseline, or a combination thereof.
  • the subject is an ambulatory ERT-naive patient and the subject’s R-PAct score at 12 months after treatment is increased by at least 2.0 compared to baseline or, the subject’s R-PAct score at 21 months after treatment is increased by at least 1.0 compared to baseline, or a combination thereof.
  • the subject is an ambulatory ERT-naive patient and the subject’s R-PAct score at 12 months after treatment is increased by about 2.8 compared to baseline, or the subject’s R-PAct score at 21 months after treatment is increased by about 1.8 compared to baseline, or a combination thereof.
  • the population of rhGAA is administered at a dosage capable of improving a patient-reported outcome as determined by Rotterdam Handicap Scale score at six, 12, 21, or 24 months after treatment compared to baseline.
  • the subject s
  • Rotterdam Handicap Scale score is stable or increased at 21 months or 24 months after treatment compared to baseline.
  • the subject may be a nonambulatory ERT-switch patient and the subject’s Rotterdam Handicap Scale score at 21 months after treatment may be increased by at least 5.0 compared to baseline.
  • the subject is a nonambulatory ERT-switch patient and the subject’s Rotterdam Handicap Scale score at six months after treatment is increased by at least 1.0 compared to baseline, the subject’s Rotterdam Handicap Scale score at 12 months after treatment is increased by at least 0.5 compared to baseline, or the subject’s Rotterdam Handicap Scale score at 21 months after treatment is increased by at least 5.0 compared to baseline, or a combination thereof.
  • the subject is a nonambulatory ERT-switch patient and the subject’s Rotterdam Handicap Scale score at six months after treatment is increased by at least 1.5 compared to baseline, or the subject’s Rotterdam Handicap Scale score at 21 months after treatment is increased by at least 5.5 compared to baseline, or a combination thereof.
  • the subject is a nonambulatory ERT-switch patient and the subject’s Rotterdam Handicap Scale score at six months after treatment is increased by about 1.5 compared to baseline, the subject’s Rotterdam Handicap Scale score at 12 months after treatment is increased by about 0.5 compared to baseline, or the subject’s Rotterdam Handicap Scale score at 21 months after treatment is increased by about 5.6 compared to baseline, or a combination thereof.
  • the subject is an ambulatory ERT-naive patient and the subject’s Rotterdam Handicap Scale score at 12 months after treatment is increased by about 0.4 compared to baseline, or the subject’s Rotterdam Handicap Scale score at 21 months after treatment is increased by about 0.1 compared to baseline, or a combination thereof.
  • the population of rhGAA is administered at a dosage capable of improving a patient-reported outcome as determined by FSS score at 12, 21, or 24 months after treatment compared to baseline.
  • the subject for example, the subject’s FSS score at 21 months or 24 months after treatment may be decreased by at least 4.0 compared to baseline.
  • the subject is a nonambulatory ERT-switch patient and exhibits an FSS score decrease of at least 15.0 at 21 months after treatment relative to baseline.
  • the subject is an ambulatory ERT-switch patient and the subject’s FSS score at 12 months after treatment is decreased by at least 8.0 compared to baseline, or the subject’s FSS score at 24 months after treatment is decreased by at least 4.0 compared to baseline, or a combination thereof.
  • the subject is an ambulatory ERT-switch patient and the subject’s FSS score at 12 months after treatment is decreased by about 8.0 compared to baseline, or the subject’s FSS score at 24 months after treatment is decreased by about 4.4 compared to baseline, or a combination thereof.
  • the subject is a nonambulatory ERT-switch patient and the subject’s FSS score at 12 months after treatment is decreased by at least 12.0 (e.g., at least 12.0 or at least 12.5) compared to baseline, or the subject’s FSS score at 21 months after treatment is decreased by at least 15.0 compared to baseline, or a combination thereof.
  • the subject is a nonambulatory ERT-switch patient and the subject’s FSS score at 12 months is decreased by about 12.5 compared to baseline, or the subject’s FSS score at 21 months after treatment is decreased by about 15.0 compared to baseline, or a combination thereof.
  • the subject is an ambulatory ERT-nafve patient and the subject’s FSS score at 12 months after treatment is decreased by at least 7.0 compared to baseline, or the subject’s FSS score at 21 months after treatment is decreased by at least 4.0 compared to baseline, or a combination thereof.
  • the subject is an ambulatory ERT-nafve patient and the subject’s FSS score at 12 months after treatment is decreased by about 7.2 compared to baseline, or the subject’s FSS score at 21 months after treatment is decreased by about 4.6 compared to baseline, or a combination thereof.
  • the population of rhGAA is administered at a dosage capable of improving a patient-reported outcome as determined by SGIC score at six, nine, 12, 15, 18, 21, or 24 months after treatment compared to baseline.
  • the subject’s SGIC score at 21 or 24 months after treatment is greater than 4.
  • the subject’s SGIC score at 21 or 24 months after treatment is at least 4.5 (somewhat improved).
  • the subject’s SGIC score at 21 months or 24 months after treatment is optionally at least 5 (much improved).
  • the subject is an ambulatory ERT-switch patient and the subject’s SGIC score at six months after treatment is at least 4.5, the subject’s SGIC score at 12 months after treatment is at least 4.5, or the subject’s SGIC score at 24 months after treatment is at least 4.5, or a combination thereof.
  • the subject is an ambulatory ERT-switch patient and the subject’s SGIC score at six months after treatment is about 5, the subject’s SGIC score at 12 months after treatment is about 4.5, or the subject’s SGIC score at 24 months after treatment is about 4.5, or a combination thereof.
  • the subject is a nonambulatory ERT-switch patient and the subject’s SGIC score at six months after treatment is at least 4.5, the subject’s SGIC score at 12 months after treatment is at least 4.5, or the subject’s SGIC score at 21 months after treatment is at least 4.5, or a combination thereof.
  • the subject is a nonambulatory ERT- switch patient and the subject’s SGIC score at six months after treatment is at least 5.0, the subject’s SGIC score at 12 months after treatment is at least 5.0, or the subject’s SGIC score at 21 months after treatment is at least 5.0, or a combination thereof.
  • the subject is a
  • nonambulatory ERT-switch patient and the subject’s SGIC score at six months after treatment is about 5.0, the subject’s SGIC score at 12 months after treatment is about 5.5, or the subject’s SGIC score at 21 months after treatment is about 5.5, or a combination thereof.
  • the subject is an ambulatory ERT-nafve patient and the subject’s SGIC score at six months after treatment is at least 4.5, the subject’s SGIC score at 12 months after treatment is at least 5.0, or the subject’s SGIC score at 21 months after treatment is at least 5.0, or a combination thereof.
  • the subject is an ambulatory ERT-nafve patient and the subject’s SGIC score at six months after treatment is about 5.5, the subject’s SGIC score at 12 months after treatment is about 6.0, or the subject’s SGIC score at 21 months after treatment is about 5.5, or a combination thereof.
  • an ERT-switch patient exhibits a lower FSS score or exhibits a higher R-PAct score, Rotterdam Handicap Scale score, or SGIC score after treatment relative to the patient’s same score type after a previous ERT with alglucosidase alfa.
  • the population of rhGAA molecules is administered at a dosage capable of reducing the levels of at least one biomarker of muscle injury, for example creatine kinase (CK), e.g., at 18 months or 24 months after treatment.
  • CK creatine kinase
  • the subject’s CK levels at 18 months after treatment are reduced by at least 30% relative to baseline and/or the subject’s CK levels at 24 months after treatment are reduced by at least 25% relative to baseline.
  • the subject may be an ambulatory ERT-switch patient and exhibit a reduction in CK levels of at least 35% at 18 months after treatment relative to baseline.
  • the subject may be a nonambulatory ERT-switch patient and exhibit a reduction in CK levels of at least 35%at 24 months after treatment relative to baseline.
  • the subject may be an ambulatory ERT- nafve patient and exhibit a reduction in CK levels of at least 50% at 18 months after treatment relative to baseline and/or a reduction in CK levels of at least 45% at 24 months after treatment relative to baseline.
  • Fig. 1A shows non-phosphorylated high mannose N-glycan, a mono-M6P N-glycan, and a bis-M6P N-glycan.
  • Fig. IB shows the chemical structure of the M6P group. Each square represents N-acetylglucosamine (GlcNAc), each circle represents mannose, and each P represents phosphate.
  • GlcNAc N-acetylglucosamine
  • Fig. 2A describes productive targeting of rhGAA via N-glycans bearing M6P to target tissues (e.g. muscle tissues of subject with Pompe Disease).
  • Fig. 2B describes non-productive drug clearance to non-target tissues (e.g. liver and spleen) or by binding of non-M6P N-glycans to non-target tissues.
  • FIG. 3 is a schematic diagram of an exemplary process for the manufacturing, capturing and purification of a recombinant lysosomal protein.
  • Fig. 4 shows a DNA construct for transforming CHO cells with DNA encoding rhGAA.
  • Fig. 5 is a graph showing the results of CIMPR affinity chromatography of ATB200 rhGAA with (Embodiment 2) and without (Embodiment 1) capture on an anion exchange (AEX) column.
  • AEX anion exchange
  • Figs. 6A-6H show the results of a site-specific N-glycosylation analysis of ATB200 rhGAA, using two different LC-MS/MS analytical techniques.
  • Fig. 6A shows the site occupancy of the seven potential N-glycosylation sites for ATB200.
  • Fig. 6B shows two analyses of the N- glycosylation profile of the first potential N-glycosylation site for ATB200.
  • Fig. 6C shows two analyses of the N-glycosylation profile of the second potential N-glycosylation site for ATB200.
  • Fig. 6D shows two analyses of the N-glycosylation profile of the third potential N-glycosylation site for ATB200.
  • Fig. 6A-6H show the results of a site-specific N-glycosylation analysis of ATB200 rhGAA, using two different LC-MS/MS analytical techniques.
  • Fig. 6A shows the site occupancy of the seven potential N-glycosylation sites for ATB200.
  • FIG. 6E shows two analyses of the N-glycosylation profile of the fourth potential N- glycosylation site for ATB200.
  • Fig. 6F shows two analyses of the N-glycosylation profile of the fifth potential N-glycosylation site for ATB200.
  • Fig. 6G shows two analyses of the N-glycosylation profile of the sixth potential N-glycosylation site for ATB200.
  • Fig. 6H summarizes the relative percent mono-phosphorylated and bis-phosphorylated species for the first, second, third, fourth, fifth, and sixth potential N-glycosylation sites.
  • Fig. 7 is a graph showing Polywax elution profiles of Lumizyme® (alglucosidase alfa, thinner line, eluting to the left) and ATB200 (thicker line, eluting to the right).
  • Fig. 8 is a table showing a summary ofN-glycan structures of Lumizyme® compared to three different preparations of ATB200 rhGAA, identified as BP-rhGAA, ATB200-1 and ATB200- 2
  • Figs. 9A and 9B are graphs showing the results of CIMPR affinity chromatography of Lumizyme® and Myozyme®, respectively.
  • Fig. 10A is a graph comparing the CIMPR binding affinity of ATB200 rhGAA (left trace) with that of Lumizyme® (right trace).
  • Fig. 10B is a table comparing the bis-M6P content of Lumizyme® and ATB200 rhGAA.
  • Fig. 11A is a graph comparing ATB200 rhGAA activity (left trace) with Lumizyme® rhGAA activity (right trace) inside normal fibroblasts at various GAA concentrations.
  • Fig. 1 IB is a table comparing ATB200 rhGAA activity (left trace) with Lumizyme® rhGAA activity (right trace) inside fibroblasts from a subject having Pompe Disease at various GAA concentrations.
  • Fig. 11C is a table comparing K up take of fibroblasts from normal subjects and subjects with Pompe Disease.
  • Fig. 12 depicts the stability of ATB200 in acidic or neutral pH buffers evaluated in a thermostability assay using SYPRO Orange, as the fluorescence of the dye increases when proteins denature.
  • Fig. 13 shows tissue glycogen content of WT mice or Gaa KO mice treated with a vehicle, alglucosidase alfa, or ATB200/AT2221, determined using amyloglucosidase digestion. Bars represent Mean ⁇ SEM of 7 mice/group. * p ⁇ 0.05 compared to alglucosidase alfa in multiple comparison using Dunnett’s method under one-way ANOVA analysis.
  • Fig. 15B shows a western blot analysis of LC3 II protein. A total of 30 mg protein was loaded in each lane.
  • Fig. 17 depicts co-immunofluore scent staining of LAMP1 (green) (see for example, “B”) and LC3 (red) (see, for example,“A”) in single fibers isolated from the white gastrocnemius of Gaa KO mice treated with a vehicle, alglucosidase alfa, or ATB200.“C” depicts clearance of autophagic debris and absence of enlarged lysosome. A minimum of 30 fibers were examined from each animal.
  • Fig. 18 depicts stabilization of ATB200 by AT2221 at 17 mM, and 170 pM AT2221, respectively, as compared to ATB200 alone.
  • Figs. 19A and 19B show the ATB200-02 study design (see also updated ATB200-02 study design in Fig. 43).
  • Low dose 130 mg.
  • High dose 260 mg.
  • LOPD late onset Pompe disease.
  • Fig. 20 depicts pharmacokinetic data for AT2221.
  • AUC area under the curve
  • CL/F plasma clearance adjusted for AT2221 oral bioavailability
  • C max maximum drug concentration
  • CV coefficient of variability
  • ti / 2 half-life
  • t max time to maximum drug concentration
  • Vz/F apparent terminal phase volume of distribution adjusted for AT2221 oral bioavailability
  • a geometric mean (CV%)
  • Fig. 21 depicts total GAA protein by signature peptide T09 for Cohorts 1 and 3.
  • Figs. 22A, 22B, 22C, 22D, 22E, and 22F depict total GAA protein by cohort.
  • Low dose 130 mg.
  • High dose 260 mg.
  • Fig. 22A shows the mean total GAA protein concentration time profiles for Cohort 1 (single dose).
  • Fig. 22B shows the mean total GAA protein concentration time profiles for Cohort 1 (multiple dose).
  • Fig. 22C shows the mean total GAA protein
  • Fig. 22D shows the mean total GAA protein concentration-time profiles for Cohort 1 vs Cohort 3 (multiple dose).
  • Fig. 23 shows an analysis of variance (ANOVA) for total GAA protein by signature peptide T09.
  • AUC area under the curve
  • Fig. 24A depicts a summary of the analyses and available interim data from the 6- Minute Walk Test (“6MWT”), showing the change from baseline (“CFBL”) at month 6, month 9, and month 12 for patients in Cohort 1 and Cohort 3.
  • 6MWT 6- Minute Walk Test
  • Fig. 24B depicts 6MWT data for individual Cohort 1 and Cohort 3 patients.
  • Fig. 24C depicts a summary of the analysis and available interim data from other motor function tests: the Timed up and Go motor function test; the 4-stair climb test; the ten-meter (10M) walk test; gowers; and the gait-stair-gower-chair (“GSGC”) motor function test, showing the change from baseline (“CFBL”) at month 6, month 9, and month 12 for patients in Cohort 1 and Cohort 3.
  • GSGC is an observer-rated combined score of four motor function assessments: gait (10- meter walk), 4-stair climb, gowers (stand from floor), and rising from chair. Each test is scored from 1 (normal) to 7 (cannot perform; max score of 6 for rising from chair test). Total scores range from 4 to 27.
  • Fig. 25 depicts a summary of the analysis and available interim data from Muscle Strength Testing (QMT), showing the change from baseline (“CFBL”) at month 6 and month 9 for patients in Cohort 2.
  • QMT quantified muscle test.
  • Fig. 26A depicts of summary of the analysis and available interim data from manual muscle test (MMT) scores in Cohort 1 patients. MMT scores were calculated for upper body (maximum score: 40), lower body (maximum score: 40), and total body (maximum score: 80).
  • Fig. 26C depicts of summary of the analysis and available interim data from manual muscle test (MMT) scores in Cohort 3 patients. MMT scores were calculated for upper body (maximum score: 40), lower body (maximum score: 40), and total body (maximum score: 80).
  • FVC forced vital capacity
  • MIP maximal inspiratory pressure
  • MEP maximal expiratory pressure
  • Fig. 28 depicts a summary of the analysis and available interim data from the Fatigue Severity Scale (“FSS”), a self-assessment questionnaire consisting of nine questions, each scored on a scale of 1 to 7. The total score ranges from 9 to 63, with higher values representing higher level of fatigue due to the disease condition. The normative value in the healthy population is ⁇ 21.
  • Fig. 28 shows the change from baseline (“CFBL”) at month 6, month 9, and month 12 for patients in Cohort 1, Cohort 2, and Cohort 3.
  • Figs. 29A-29C depict the mean percentage change from baseline in markers of marker injury (alanine aminotransferase, aspartate aminotransferase, and creatine kinase) in all patient cohorts.
  • Fig. 29A depicts data from Cohort 1 patients over 58 weeks
  • Fig. 29B depicts data from Cohort 2 patients over 24 weeks
  • Fig. 29C depicts data from Cohort 3 patients over 36 weeks.
  • Fig. 31 summarizes available efficacy and safety data from the ATB200-02 study.
  • Figs. 32A-32H show the results of a site-specific N-glycosylation analysis of ATB200 rhGAA, including an N-glycosylation profile for the seventh potential N-glycosylation site, using LC-MS/MS analysis of protease-digested ATB200.
  • Figs. 32A-32H provide average data for ten lots of ATB200 produced at different scales.
  • Fig. 32A shows the average site occupancy of the seven potential N-glycosylation sites for ATB200.
  • the N-glycosylation sites are provided according to SEQ ID NO: 1.
  • CV coefficient of variation.
  • Figs. 32B-32H show the site-specific N-glycosylation analyses of all seven potential N-glycosylation sites for ATB200, with site numbers provided according to SEQ ID NO: 5. Bars represent the maximum and minimum percentage of N-glycan species identified as a particular N- glycan group for the ten lots of ATB200 analyzed.
  • Fig. 32B shows the N-glycosylation profile of the first potential N-glycosylation site for ATB200.
  • Fig. 32C shows the N-glycosylation profile of the second potential N-glycosylation site for ATB200.
  • Fig. 32D shows the N-glycosylation profile of the third potential N-glycosylation site for ATB200.
  • FIG. 32E shows the N-glycosylation profile of the fourth potential N-glycosylation site for ATB200.
  • Fig. 32F shows the N-glycosylation profile of the fifth potential N-glycosylation site for ATB200.
  • Fig. 32G shows the N-glycosylation profile of the sixth potential N-glycosylation site for ATB200.
  • Fig. 32H shows the N-glycosylation profile of the seventh potential N-glycosylation site for ATB200.
  • Figs. 33A-33B further characterize and summarize the N-glycosylation profile of ATB200, as also shown in Figs. 32A-32H.
  • Fig. 33A shows 2-Anthranilic acid (2-AA) glycan mapping and LC/MS-MS analysis of ATB200 and summarizes the N-glycan species identified in ATB200 as a percentage of total fluorescence. Data from 2-AA glycan mapping and LC-MS/MS analysis are also depicted in Table 5.
  • Fig. 33B summarizes the average site occupancy and average N-glycan profile, including total phosphorylation, mono-phosphorylation, bis-phosphorylation, and sialylation, for all seven potential N-glycosylation sites for ATB200.
  • Fig. 34 shows the ATB200-02 study design with long-term extension.
  • Fig. 35 summarizes updated baseline characteristics of patients enrolled across Cohorts 1, 2, and 3.
  • Fig. 36 depicts a summary of the analyses and available interim data up to 24 months from the 6-Minute Walk Test (“6MWT”), showing the change from baseline (“CFBL”) at month 6, month 12, and month 24 for patients in Cohort 1 and Cohort 3.
  • 6MWT 6-Minute Walk Test
  • Fig. 37 depicts a summary of the analysis and available interim data up to 24 months from other motor function tests: the Timed up and Go motor function test; the 4-stair climb test; the ten -meter (10M) walk test; gowers; and the gait-stair-gower-chair (“GSGC”) motor function test, showing the change from baseline (“CFBL”) at month 6, month 9, and month 12 for patients in Cohort 1 and Cohort 3.
  • Fig. 38 depicts a summary of the analysis and available interim data up to 24 months from Manual Muscle Strength Testing, showing the change from baseline (“CFBL”) at month 6, month 12, and month 21 or 24 for patients in Cohorts 1, 2, and 3.
  • MMT manual muscle testing.
  • MMT Scoring 1) Visible muscle movement, but no movement at the joint; 2) Movement at the joint, but not against gravity; 3) Movement against gravity, but not against added resistance; 4) Movement against resistance, but less than normal; 5) Normal strength. MMT scoring is the total for left and right sides combined. [083] Fig.
  • R-PAct is an 18-term questionnaire to measure limitations in activities and social participation in patients with Pompe disease; each activity is ranked from 0 (no) to 2 (yes, without difficulty); total scores range from 0 to 36, with lower scores representing more limitations.
  • the Rotterdam Handicap Scale is a 9-item questionnaire to measure functional ability and level of handicap; each item is ranked from 1 (unable to perform task) to 4 (able to perform task independently); total scores range from 9 to 36; lower scores represent worse functioning.
  • the Fatigue Severity Scale (“FSS”) is a self-assessment questionnaire consisting of nine questions, each scored on a scale of 1 to 7. The total score ranges from 9 to 63, with higher values representing higher level of fatigue due to the disease condition.
  • the normative value in the healthy population is ⁇ 27.
  • Fig. 41 depicts a summary of the analysis and available interim data for Subject Global Impression of Change (“SGIC”) up to 24 months, showing change from baseline at month 6, month 9, month 12, month 15, month 18, and month 21 for patients in Cohorts 1, 2, and 3, and at month 24 for patients in Cohort 1.
  • CK creatine kinase
  • Hex4 urine hexose tetrasaccharide
  • BL baseline
  • Hex4 urine hexose tetrasaccharide
  • M month
  • SE standard error
  • W week.
  • Fig. 43 shows an updated ATB200-02 study design, including the patient and dosing information for Cohort 4.
  • Fig. 44 summarizes the baseline characteristics of patients enrolled across Cohorts 1- 4.
  • Fig. 45 depicts a summary of the data from the 6-Minute Walk Test (“6MWT”), showing the changes from baseline (“CFBL”) at month 6, month 12, and month 24 for patients in Cohort 1 and Cohort 3.
  • 6MWT 6-Minute Walk Test
  • Fig. 46 depicts a summary of the data from Sitting Forced Vital Capacity (“FVC”), showing the changes from baseline (“CFBL”) at month 6, month 12, and month 24 for patients in Cohort 1 and Cohort 3.
  • FVC Forced Vital Capacity
  • Fig. 47 depicts a summary of the data from the Manual Muscle Test (MMT) scores, showing the changes from baseline (“CFBL”) at month 6, month 12, and month 24 for patients in Cohorts 1-3.
  • MMT Manual Muscle Test
  • Fig. 48 depicts a summary of the data from the Timed Motor Function Test (TMFT) scores, showing the changes from baseline (“CFBL”) at month 6, month 12, and month 24 for patients in Cohort 1 and Cohort 3.
  • TMFT Timed Motor Function Test
  • Fig. 49 depicts a summary of the data from the Fatigue Severity Scale (“FSS”), a self-assessment questionnaire consisting of nine questions, each scored on a scale of 1 to 7. The data shows the changes from baseline (“CFBL”) at month 6, month 12, and month 24 for patients in Cohorts 1-3.
  • FSS Fatigue Severity Scale
  • Fig. 50 shows a clinical assessment summary for patients in Cohort 4.
  • Fig. 51 depicts a summary of the data for Subject Global Impression of Change (“SGIC”), showing changes from baseline (“CFBL”) at month 6, month 9, month 12, month 15, month 18, month 21, and month 24 for patients in Cohorts 1-3, and up to month 15 for patients in Cohort 4.
  • SGIC Subject Global Impression of Change
  • Fig. 52A depicts a summary of the data for the muscle damage biomarker creatine kinase (CK), showing changes from baseline (“CFBL”) at month 3, month 6, month 9, month 12, month 15, month 18, month 21, and month 24 for patients in Cohorts 1-3, and up to month 15 for patients in Cohort 4.
  • CK creatine kinase
  • Fig. 52B depicts a summary of the data for the disease substrate biomarker urine hexose tetrasaccharide (Hex4), showing changes from baseline (“CFBL”) at month 3, month 6, month 9, month 12, month 15, month 18, month 21, and month 24 for patients in Cohorts 1-3, and up to month 12 for patients in Cohort 4.
  • CFBL disease substrate biomarker urine hexose tetrasaccharide
  • Fig. 53 summarizes safety data from the updated ATB200-02 study.
  • Fig. 54 shows updated conclusions from the ATB200-02 study.
  • GAA refers to human acid a-glucosidase (GAA) enzyme that catalyzes the hydrolysis of a- 1,4- and a-l,6-glycosidic linkages of lysosomal glycogen as well as to insertional, relational, or substitution variants of the GAA amino acid sequence and fragments of a longer GAA sequence that exert enzymatic activity.
  • Human acid a-glucosidase is encoded by the GAA gene (National Centre for Biotechnology Information (NCBI) Gene ID 2548), which has been mapped to the long arm of chromosome 17 (location 17q25.2-q25.3).
  • GAA GAA
  • NP 000143.2 An exemplary amino acid sequence of GAA is NP 000143.2, which is incorporated by reference. This disclosure also encompasses DNA sequences that encode the amino acid sequence of NP 000143.2. More than 500 mutations have currently been identified in the human GAA gene, many of which are associated with Pompe disease. Mutations resulting in misfolding or misprocessing of the acid a-glucosidase enzyme include T1064C (Leu355Pro) and C2104T (Arg702Cys). In addition, GAA mutations which affect maturation and processing of the enzyme include Leu405Pro and Met519Thr. The conserved hexapeptide WIDMNE at amino acid residues 516-521 is required for activity of the acid a-glucosidase protein.
  • the abbreviation“GAA” is intended to refer to human acid a-glucosidase enzyme
  • the italicized abbreviation“ GAA” is intended to refer to the human gene coding for the human acid a- glucosidase enzyme
  • the italicized abbreviation“Goo” is intended to refer to non-human genes coding for non-human acid a-glucosidase enzymes, including but not limited to rat or mouse genes
  • the abbreviation“Gaa” is intended to refer to non-human acid a-glucosidase enzymes.
  • the term“rhGAA” is intended to refer to the recombinant human acid a-glucosidase enzyme and is used to distinguish endogenous GAA from synthetic or recombinant-produced GAA (e.g., GAA produced from CHO cells transformed with DNA encoding GAA).
  • the term“rhGAA” encompasses a population of individual rhGAA molecules. Characteristics of the population of rhGAA molecules are provided herein.
  • the term“conventional rhGAA product” is intended to refer to products containing alglucosidase alfa, such as Lumizyme® or Myozyme®.
  • the term“genetically modified” or“recombinant” refers to cells, such as CHO cells, that express a particular gene product, such as rhGAA, following introduction of a nucleic acid comprising a coding sequence which encodes the gene product, along with regulatory elements that control expression of the coding sequence.
  • Introduction of the nucleic acid may be accomplished by any method known in the art including gene targeting and homologous recombination.
  • the term also includes cells that have been engineered to express or overexpress an endogenous gene or gene product not normally expressed by such cell, e.g., by gene activation technology.
  • alglucosidase alfa is intended to refer to a recombinant human acid a-glucosidase identified as [199-arginine, 223-histidine]prepro-a-glucosidase (human); Chemical Abstracts Registry Number 420794-05-0. Alglucosidase alfa is approved for marketing in the United States by Genzyme, as the products Lumizyme® and Myozyme®.
  • ATB200 is intended to refer to a recombinant human acid a-glucosidase described in International Application PCT/US2015/053252, the disclosure of which is herein incorporated by reference.
  • the term“glycan” is intended to refer to an oligosaccharide covalently bound to an amino acid residue on a protein or polypeptide.
  • the term“N- glycan” or “N-linked glycan” is intended to refer to a polysaccharide chain attached to an asparagine residue on a protein or polypeptide through covalent binding to a nitrogen atom of the asparagine residue.
  • the N-glycan units attached to a rhGAA are determined by liquid chromatography- tandem mass spectrometry (LC-MS/MS) utilizing an instrument such as the Thermo ScientificTM Orbitrap Velos ProTM Mass Spectrometer, Thermo ScientificTM Orbitrap FusionTM Lumos TribidTM Mass Spectrometer, or Waters Xevo® G2-XS QTof Mass Spectrometer.
  • LC-MS/MS liquid chromatography- tandem mass spectrometry
  • forced vital capacity is the amount of air that can be forcibly exhaled from the lungs of a subject after the subject takes the deepest breath possible.
  • a“six-minute walk test” (6MWT) is a test for measuring the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The test is conducted by having the individual to walk as far as possible in six minutes.
  • a“ten-meter walk test” 10MWT is a test for measuring the time it takes an individual in walking shoes to walk ten meters on a flat surface.
  • the compound miglustat also known as N-butyl-l-deoxynojirimycin or NB- DNJ or (2R,3R,4R,5S)-l-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol, is a compound having the following chemical formula:
  • miglustat is marketed commercially under the trade name Zavesca® as monotherapy for type 1 Gaucher disease. In some embodiments, miglustat is referred to as AT2221.
  • salts of miglustat may also be used in the present invention.
  • the dosage of the salt will be adjusted so that the dose of miglustat received by the patient is equivalent to the amount which would have been received had the miglustat free base been used.
  • the compound duvoglustat also known as 1-deoxynojirimycin or DNJ or (2R,3R,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol, is a compound having the following chemical formula:
  • the term“pharmacological chaperone” or sometimes simply the term “chaperone” is intended to refer to a molecule that specifically binds to acid a-glucosidase and has one or more of the following effects:
  • a pharmacological chaperone for acid a-glucosidase is a molecule that binds to acid a-glucosidase, resulting in proper folding, trafficking, non-aggregation, and activity of acid a- glucosidase.
  • this term includes but is not limited to active site-specific chaperones (ASSCs) which bind in the active site of the enzyme, inhibitors or antagonists, and agonists.
  • the pharmacological chaperone can be an inhibitor or antagonist of acid a- glucosidase.
  • the term“antagonist” is intended to refer to any molecule that binds to acid a-glucosidase and either partially or completely blocks, inhibits, reduces, or neutralizes an activity of acid a-glucosidase.
  • the pharmacological chaperone is miglustat.
  • Another non-limiting example of a pharmacological chaperone for acid a-glucosidase is duvoglustat.
  • the term“pharmaceutically acceptable” is intended to refer to molecular entities and compositions that are physiologically tolerable and do not typically produce untoward reactions when administered to a human.
  • the term “pharmaceutically acceptable” is intended to refer to molecular entities and compositions that are physiologically tolerable and do not typically produce untoward reactions when administered to a human.
  • the term “pharmaceutically acceptable” is intended to refer to molecular entities and compositions that are physiologically tolerable and do not typically produce untoward reactions when administered to a human.
  • the term“pharmaceutically acceptable” is intended to refer to molecular entities and compositions that are physiologically tolerable and do not typically produce untoward reactions when administered to a human.
  • “pharmaceutically acceptable” means approved by a regulatory agency of the federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • the term“carrier” is intended to refer to a diluent, adjuvant, excipient, or vehicle with which a compound is administered. Suitable
  • pharmaceutically acceptable salt as used herein is intended to mean a salt which is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, generally water or oil-soluble or dispersible, and effective for their intended use.
  • the term includes pharmaceutically -acceptable acid addition salts and pharmaceutically -acceptable base addition salts. Lists of suitable salts are found in, for example, S. M. Berge et ah, J. Pharm. Sci., 1977, 66, pp. 1 -19, herein incorporated by reference.
  • pharmaceutically -acceptable acid addition salt as used herein is intended to mean those salts which retain the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable, formed with inorganic acids.
  • pharmaceutically -acceptable base addition salt as used herein is intended to mean those salts which retain the biological effectiveness and properties of the free acids and which are not biologically or otherwise undesirable, formed with inorganic bases.
  • buffer refers to a solution containing a weak acid and its conjugate base or a weak base and its conjugate acid that helps to prevent changes in pH.
  • the terms“therapeutically effective dose” and“effective amount” are intended to refer to an amount of acid a-glucosidase and/or of miglustat and/or of a combination thereof, which is sufficient to result in a therapeutic response in a subject.
  • the therapeutic response may also include molecular responses such as glycogen accumulation, lysosomal proliferation, and formation of autophagic zones.
  • the therapeutic responses may be evaluated by comparing physiological and molecular responses of muscle biopsies before and after treatment with a rhGAA described herein. For instance, the amount of glycogen present in the biopsy samples can be used as a marker for determining the therapeutic response.
  • Another example includes biomarkers such as LAMP-1, LC3, and Dysferlin, which can be used as an indicator of lysosomal storage dysfunction. For instance, muscle biopsies collected prior to and after treatment with a rhGAA described herein may be stained with an antibody that recognizes one of the biomarkers.
  • the therapeutic response may also include a decrease in fatigue or improvement in other patient-reported outcomes (e.g., daily living activities, well-being, etc.).
  • the term“enzyme replacement therapy” or“ERT” is intended to refer to the introduction of a non-native, purified enzyme into an individual having a deficiency in such enzyme.
  • the administered protein can be obtained from natural sources or by recombinant expression.
  • the term also refers to the introduction of a purified enzyme in an individual otherwise requiring or benefiting from administration of a purified enzyme. In at least one embodiment, such an individual suffers from enzyme insufficiency.
  • the introduced enzyme may be a purified, recombinant enzyme produced in vitro, or a protein purified from isolated tissue or fluid, such as, for example, placenta or animal milk, or from plants.
  • the term“combination therapy” is intended to refer to any therapy wherein two or more individual therapies are administered concurrently or sequentially.
  • the results of the combination therapy are enhanced as compared to the effect of each therapy when it is performed individually. Enhancement may include any improvement of the effect of the various therapies that may result in an advantageous result as compared to the results achieved by the therapies when performed alone.
  • Enhanced effect or results can include a synergistic enhancement, wherein the enhanced effect is more than the additive effects of each therapy when performed by itself; an additive enhancement, wherein the enhanced effect is substantially equal to the additive effect of each therapy when performed by itself; or less than additive effect, wherein the enhanced effect is lower than the additive effect of each therapy when performed by itself, but still better than the effect of each therapy when performed by itself.
  • Enhanced effect may be measured by any means known in the art by which treatment efficacy or outcome can be measured.
  • Pompe Disease refers to an autosomal recessive LSD characterized by deficient acid alpha glucosidase (GAA) activity which impairs lysosomal glycogen metabolism.
  • GAA acid alpha glucosidase
  • the enzyme deficiency leads to lysosomal glycogen accumulation and results in progressive skeletal muscle weakness, reduced cardiac function, respiratory insufficiency, and/or CNS impairment at late stages of disease.
  • Genetic mutations in the GAA gene result in either lower expression or produce mutant forms of the enzyme with altered stability, and/or biological activity ultimately leading to disease,
  • Infantile Pompe disease (type I or A) is most common and most severe, characterized by failure to thrive, generalized hypotonic, cardiac hypertrophy, and cardiorespiratory failure within the second year of life.
  • Juvenile Pompe disease (type II or B) is intermediate in severity and is characterized by a predominance of muscular symptoms without cardiomegaly. Juvenile Pompe individuals usually die before reaching 20 years of age due to respiratory failure.
  • A“subject” or“patient” is preferably a human, though other mammals and non human animals having disorders involving accumulation of glycogen may also be treated.
  • a subject may be a fetus, a neonate, child, juvenile, or an adult with Pompe disease or other glycogen storage or accumulation disorder.
  • One example of an individual being treated is an individual (fetus, neonate, child, juvenile, adolescent, or adult human) having GSD-II (e.g., infantile GSD-II, juvenile GSD-II, or adult-onset GSD-II).
  • the individual can have residual GAA activity, or no measurable activity.
  • the individual having GSD-II can have GAA activity that is less than about 1% of normal GAA activity (infantile GSD-II), GAA activity that is about 1-10% of normal GAA activity (juvenile GSD-II), or GAA activity that is about 10-40% of normal GAA activity (adult GSD-II).
  • the subject or patient is an“ERT-experienced” or“ERT-switch” patient, referring to a Pompe disease patient who has previously received enzyme replacement therapy.
  • the subject or patient is an“ERT-naive” patient, referring to a Pompe disease patient who has not previously received enzyme replacement therapy.
  • the subject or patient is ambulatory (e.g., an ambulatory ERT-switch patient or an ambulatory ERT-naive patient).
  • the subject or patient is nonambulatory (e.g., a nonambulatory ERT-switch patient).
  • Ambulatory or nonambulatory status may be determined by a six-minute walk test (6MWT).
  • 6MWT six-minute walk test
  • an ambulatory patient is a Pompe disease patient who is able to walk at least 200 meters in the 6MWT.
  • a nonambulatory patient is a Pompe disease patient who is unable to walk unassisted or who is wheelchair bound.
  • treatment refers to amelioration of one or more symptoms associated with the disease, prevention or delay of the onset of one or more symptoms of the disease, and/or lessening of the severity or frequency of one or more symptoms of the disease.
  • treatment can refer to improvement of cardiac status (e.g.
  • treatment includes improvement of cardiac status, particularly in reduction or prevention of GSD-II-associated cardiomyopathy.
  • the terms“improve,”“increase,” and“reduce,” as used herein, indicate values that are relative to a baseline measurement, such as a measurement in the same individual prior to initiation of the treatment described herein, or a measurement in a control individual (or multiple control individuals) in the absence of the treatment described herein.
  • a control individual is an individual afflicted with the same form of GSD-II (either infantile, juvenile, or adult-onset) as the individual being treated, who is about the same age as the individual being treated (to ensure that the stages of the disease in the treated individual and the control individual(s) are comparable).
  • the degree of error can be indicated by the number of significant figures provided for the measurement, as is understood in the art, and includes but is not limited to a variation of ⁇ 1 in the most precise significant figure reported for the measurement. Typical exemplary degrees of error are within 20 percent (%), preferably within 10%, and more preferably within 5% of a given value or range of values. Numerical quantities given herein are approximate unless stated otherwise, meaning that the term“about” or“approximately” can be inferred when not expressly stated.
  • the recombinant human acid a-glucosidase is an enzyme having an amino acid sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6.
  • the rhGAA is encoded by a nucleotide sequence as set forth in SEQ ID NO: 2.
  • the rhGAA has a GAA amino acid sequence as set forth in SEQ ID NO: 1, as described in US Patent No. 8,592,362 and has GenBank accession number AHE24104.1 (GE568760974). In some embodiments, the rhGAA has a GAA amino acid sequence as encoded in SEQ ID NO: 2, the mRNA sequence having GenBank accession number Y00839.1. In some embodiments, the rhGAA has a GAA amino acid sequence as set forth in SEQ ID NO: 3. In at some embodiments, the rhGAA has a GAA amino acid sequence as set forth in SEQ ID NO: 4, and has National Center for Biotechnology Information (NCBI) accession number NP_000143.2 or UniProtKB Accession Number P10253.
  • NCBI National Center for Biotechnology Information
  • the rhGAA is initially expressed as having the full-length 952 amino acid sequence of wild-type GAA as set forth in SEQ ID NO: 1 or SEQ ID NO: 4, and the rhGAA undergoes intracellular processing that removes a portion of the amino acids, e.g. the first 56 amino acids. Accordingly, the rhGAA that is secreted by the host cell can have a shorter amino acid sequence than the rhGAA that is initially expressed within the cell. In some embodiments, the shorter protein has the amino acid sequence set forth in SEQ ID NO: 5, which only differs from SEQ ID NO:
  • the shorter protein has the amino acid sequence set forth in SEQ ID NO: 6, which only differs from SEQ ID NO: 4 in that the first 56 amino acids comprising the signal peptide and precursor peptide have been removed, thus resulting in a protein having 896 amino acids.
  • Other variations in the number of amino acids are also possible, such as having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more deletions, substitutions and/or insertions relative to the amino acid sequence described by SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6.
  • the rhGAA product includes a mixture of recombinant human acid a-glucosidase molecules having different amino acid lengths.
  • the rhGAA comprises an amino acid sequence that is at least 90%, 95%, 98% or 99% identical to SEQ ID NO: 4 or SEQ ID NO: 6.
  • Various alignment algorithms and/or programs may be used to calculate the identity between two sequences, including FASTA, or BLAST which are available as a part of the GCG sequence analysis package (University of
  • polypeptides having at least 90%, 95%, 98% or 99% identity to specific polypeptides described herein and preferably exhibiting substantially the same functions, as well as polynucleotide encoding such polypeptides, are contemplated. Unless otherwise indicated a similarity score will be based on use of BLOSUM62. When BLASTP is used, the percent similarity is based on the BLASTP positives score and the percent sequence identity is based on the BLASTP identities score.
  • BLASTP“Identities” shows the number and fraction of total residues in the high scoring sequence pairs which are identical; and BLASTP“Positives” shows the number and fraction of residues for which the alignment scores have positive values and which are similar to each other.
  • Amino acid sequences having these degrees of identity or similarity or any intermediate degree of identity of similarity to the amino acid sequences disclosed herein are contemplated and encompassed by this disclosure.
  • the polynucleotide sequences of similar polypeptides are deduced using the genetic code and may be obtained by conventional means, in particular by reverse translating its amino acid sequence using the genetic code.
  • the rhGAA undergoes post-translational and/or chemical modifications at one or more amino acid residues in the protein.
  • methionine and tryptophan residues can undergo oxidation.
  • the N-terminal glutamine in SEQ ID NO: 6 can be further modified to form pyro-glutamate.
  • asparagine residues can undergo deamidation to aspartic acid.
  • aspartic acid residues can undergo isomerization to iso-aspartic acid.
  • unpaired cysteine residues in the protein can form disulfide bonds with free glutathione and/or cysteine.
  • the enzyme is initially expressed as having an amino acid sequence as set forth in SEQ ID NO: 1,
  • SEQ ID NO: 3 SEQ ID NO: 4, or SEQ ID NO: 5, or an amino acid sequence encoded by SEQ ID NO: 2, and the enzyme undergoes one or more of these post-translational and/or chemical modifications. Such modifications are also within the scope of the present disclosure.
  • N-linked glycosylation sites There are seven potential N-linked glycosylation sites on a single rhGAA molecule. These potential glycosylation sites are at the following positions of SEQ ID NO: 6: N84, N177, N334, N414, N596, N826, and N869. Similarly, for the full-length amino acid sequence of SEQ ID NO: 4, these potential glycosylation sites are at the following positions: N140, N233, N390, N470, N652, N882, and N925. Other variants of rhGAA can have similar glycosylation sites, depending on the location of asparagine residues. Generally, sequences of Asn-X-Ser or Asn-X-Thr in the protein amino acid sequence indicate potential glycosylation sites, with the exception that X cannot be His or Pro.
  • the rhGAA molecules described herein may have, on average, 1, 2, 3, or 4 mannose- 6-phosphate (M6P) groups on their N-glycans.
  • M6P mannose- 6-phosphate
  • only one N-glycan on a rhGAA molecule may bear M6P (mono-phosphorylated or mono-M6P)
  • a single N-glycan may bear two M6P groups (bis-phosphorylated or bis-M6P)
  • two different N-glycans on the same rhGAA molecule may each bear single M6P groups.
  • the rhGAA molecules described herein on average have 3-4 M6P groups on their N-glycans.
  • Recombinant human acid a-glucosidase molecules may also have N-glycans bearing no M6P groups.
  • the rhGAA comprises greater than 2.5 mol M6P per mol rhGAA and greater than 4 mol sialic acid per mol rhGAA.
  • the rhGAA comprises about 3-3.5 mol M6P per mol rhGAA.
  • the rhGAA comprises about 4-5.4 mol sialic acid per mol rhGAA.
  • the total N-glycans on the rhGAA may be in the form of a mono-M6P N-glycan, for example, about 6.25% of the total N- glycans may carry a single M6P group and on average, at least about 0.5, 1, 1.5, 2.0, 2.5, 3.0% of the total N-glycans on the rhGAA are in the form of a bis-M6P N-glycan and on average less than 25% of total rhGAA contains no phosphorylated N-glycan binding to CIMPR.
  • the rhGAA comprises about 1.3 mol bis-M6P per mol rhGAA.
  • the rhGAA described herein may have an average content of N-glycans carrying M6P ranging from 0.5 to 7.0 mol M6P per mol rhGAA or any intermediate value or subrange thereof including 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, or 7.0 mol M6P per mol rhGAA.
  • the rhGAA can be fractionated to provide rhGAA preparations with different average numbers of mono-M6P-bearing or bis-M6P-bearing N-glycans, thus permitting further customization of rhGAA targeting to the lysosomes in target tissues by selecting a particular fraction or by selectively combining different fractions.
  • up to 60% of the N-glycans on the rhGAA may be fully sialylated, for example, up to 10%, 20%, 30%, 40%, 50% or 60% of the N-glycans may be fully sialylated. In some embodiments, no more than 50% of the N-glycans on the rhGAA are fully sialylated. In some embodiments, from 4% to 20% of the total N-glycans are fully sialylated. In other embodiments, no more than 5%, 10%, 20% or 30% of N-glycans on the rhGAA carry sialic acid and a terminal galactose residue (Gal).
  • Gal galactose residue
  • This range includes all intermediate values and subranges, for example, 7% to 30% of the total N-glycans on the rhGAA can carry sialic acid and terminal galactose. In yet other embodiments, no more than 5%, 10%, 15%, 16%, 17%, 18%, 19%, or 20% of the N- glycans on the rhGAA have a terminal galactose only and do not contain sialic acid. This range includes all intermediate values and subranges, for example, from 8% to 19% of the total N-glycans on the rhGAA in the composition may have terminal galactose only and do not contain sialic acid.
  • 40%, 45%, 50%, or 55% to 60% of the total N-glycans on the rhGAA are complex type N-glycans; or no more than 1%, 2%, 3%, 4%, 5%, 6,%, or 7% of total N- glycans on the rhGAA are hybrid-type N-glycans; no more than 5%, 10%, 15%, 20%, or 25% of the high mannose-type N-glycans on the rhGAA are non-phosphorylated; at least 5% or 10% of the high mannose-type N-glycans on the rhGAA are mono-phosphorylated; and/or at least 1% or 2% of the high mannose-type N-glycans on the rhGAA are bis-phosphorylated. These values include all intermediate values and subranges.
  • a rhGAA may meet one or more of the content ranges described above.
  • the rhGAA may bear, on average, 2.0 to 8.0 moles of sialic acid residues per mole of rhGAA. This range includes all intermediate values and subranges thereof, including 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, and 8.0 mol sialic acid residues per mol rhGAA. Without being bound by theory, it is believed that the presence of N-glycan units bearing sialic acid residues may prevent non-productive clearance of the rhGAA by asialoglycoprotein receptors.
  • the rhGAA has a certain N-glycosylation profde at certain potential N-glycosylation sites. In some embodiments, the rhGAA has seven potential N- glycosylation sites. In some embodiments, at least 20% of the rhGAA is phosphorylated at the first potential N-glycosylation site (e.g., N84 for SEQ ID NO: 6 and N140 for SEQ ID NO: 4). For example, at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the rhGAA can be phosphorylated at the first potential N-glycosylation site.
  • the first potential N-glycosylation site e.g., N84 for SEQ ID NO: 6 and N140 for SEQ ID NO: 4
  • This phosphorylation can be the result of mono-M6P and/or bis-M6P units.
  • at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the rhGAA bears a mono-M6P unit at the first potential N-glycosylation site.
  • at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the rhGAA bears a bis-M6P unit at the first potential N- glycosylation site.
  • the rhGAA comprises on average about 1.4 mol M6P (mono-M6P and bis-M6P) per mol rhGAA at the first potential N-glycosylation site. In some embodiments, the rhGAA comprises on average about at least 0.5 mol bis-M6P per mol rhGAA at the first potential N-glycosylation site. In some embodiments, the rhGAA comprises on average about 0.25 mol mono-M6P per mol rhGAA at the first potential N-glycosylation site. In some
  • the rhGAA comprises on average about 0.2 mol to about 0.3 mol sialic acid per mol rhGAA at the first potential N-glycosylation site.
  • the rhGAA comprises a first potential N-glycosylation site occupancy as depicted in Fig. 6A and an N-glycosylation profile as depicted in Fig. 6B.
  • the rhGAA comprises a first potential N- glycosylation site occupancy as depicted in Fig. 32A and an N-glycosylation profile as depicted in Fig. 32B or Fig. 33B.
  • At least 20% of the rhGAA is phosphorylated at the second potential N-glycosylation site (e.g., N177 for SEQ ID NO: 6 and N223 for SEQ ID NO: 4).
  • the second potential N-glycosylation site e.g., N177 for SEQ ID NO: 6 and N223 for SEQ ID NO: 4
  • at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the rhGAA can be phosphorylated at the second N-glycosylation site.
  • This phosphorylation can be the result of mono-M6P and/or bis-M6P units.
  • At least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the rhGAA bears a mono-M6P unit at the second N-glycosylation site. In some embodiments, at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the rhGAA bears a bis-M6P unit at the second N-glycosylation site.
  • the rhGAA comprises on average about 0.5 mol M6P (mono-M6P and bis-M6P) per mol rhGAA at the second potential N-glycosylation site. In some embodiments, the rhGAA comprises on average about 0.4 to about 0.6 mol mono-M6P per mol rhGAA at the second potential N-glycosylation site. In at least one embodiment, the rhGAA comprises a second potential N- glycosylation site occupancy as depicted in Fig. 6A and an N-glycosylation profile as depicted in Fig. 6C. In at least one embodiment, the rhGAA comprises a second potential N-glycosylation site occupancy as depicted in Fig. 32A and an N-glycosylation profile as depicted in Fig. 32C or Fig. 33B.
  • the rhGAA is phosphorylated at the third potential N-glycosylation site (e.g., N334 for SEQ ID NO: 6 and N390 for SEQ ID NO: 4). In other embodiments, less than 5%, 10%, 15%, 20%, or 25% of the rhGAA is phosphorylated at the third potential N-glycosylation site.
  • the third potential N-glycosylation site can have a mixture of non-phosphorylated high mannose N-glycans, di-, tri-, and tetra-antennary complex N- glycans, and hybrid N-glycans as the major species.
  • the rhGAA comprises on average about 0.9 to about 1.2 mol sialic acid per mol rhGAA at the third potential N-glycosylation site.
  • the rhGAA comprises a third potential N-glycosylation site occupancy as depicted in Fig. 6A and an N-glycosylation profile as depicted in Fig. 6D.
  • the rhGAA comprises a third potential N-glycosylation site occupancy as depicted in Fig. 32A and an N-glycosylation profile as depicted in Fig. 32D or Fig. 33B.
  • At least 20% of the rhGAA is phosphorylated at the fourth potential N-glycosylation site (e.g., N414 for SEQ ID NO: 6 and N470 for SEQ ID NO: 4).
  • the fourth potential N-glycosylation site e.g., N414 for SEQ ID NO: 6 and N470 for SEQ ID NO: 4
  • at least 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the rhGAA can be phosphorylated at the fourth potential N-glycosylation site.
  • This phosphorylation can be the result of mono-M6P and/or bis-M6P units.
  • At least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the rhGAA bears a mono-M6P unit at the fourth potential N-glycosylation site. In some embodiments, at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95% of the rhGAA bears a bis-M6P unit at the fourth potential N- glycosylation site.
  • the rhGAA comprises on average about 1.4 mol M6P (mono-M6P and bis-M6P) per mol rhGAA at the fourth potential N-glycosylation site. In some embodiments, the rhGAA comprises on average about 0.4 to about 0.6 mol bis-M6P per mol rhGAA at the fourth potential N-glycosylation site.
  • the rhGAA comprises on average about 0.3 to about 0.4 mol mono-M6P per mol rhGAA at the fourth potential N-glycosylation site.
  • the rhGAA comprises a fourth potential N-glycosylation site occupancy as depicted in Fig. 6A and an N- glycosylation profde as depicted in Fig. 6E.
  • the rhGAA comprises a fourth potential N-glycosylation site occupancy as depicted in Fig. 32A and an N-glycosylation profde as depicted in Fig. 32E or Fig. 33B.
  • the rhGAA is phosphorylated at the fifth potential N-glycosylation site (e.g., N596 for SEQ ID NO: 6 and N692 for SEQ ID NO: 4). In other embodiments, less than 5%, 10%, 15%, 20%, or 25% of the rhGAA is phosphorylated at the fifth potential N-glycosylation site.
  • the fifth potential N-glycosylation site can have fucosylated di-antennary complex N-glycans as the major species.
  • the rhGAA comprises on average about 0.8 to about 0.9 mol sialic acid per mol rhGAA at the fifth potential N-glycosylation site.
  • the rhGAA comprises a fifth potential N-glycosylation site occupancy as depicted in Fig. 6A and an N-glycosylation profile as depicted in Fig. 6F.
  • the rhGAA comprises a fifth potential N- glycosylation site occupancy as depicted in Fig. 32A and an N-glycosylation profile as depicted in Fig. 32F or Fig. 33B.
  • the rhGAA is phosphorylated at the sixth N- glycosylation site (e.g. N826 for SEQ ID NO: 6 and N882 for SEQ ID NO: 4). In other embodiments, less than 5%, 10%, 15%, 20% or 25% of the rhGAA is phosphorylated at the sixth N-glycosylation site.
  • the sixth N-glycosylation site can have a mixture of di-, tri-, and tetra-antennary complex N-glycans as the major species.
  • the rhGAA comprises on average about 1.5 to about 4.2 mol sialic acid per mol rhGAA at the sixth potential N- glycosylation site. In some embodiments, the rhGAA comprises on average about 0.9 mol acetylated sialic acid per mol rhGAA at the sixth potential N-glycosylation site.
  • the rhGAA comprises an average of at least 0.05 mol glycan species with poly-N-Acetyl-D-lactosamine (poly-LacNAc) residues per mol rhGAA at the sixth potential N-glycosylation site. In some embodiments, over 10% of the rhGAA comprises a glycan bearing a poly-LacNAc residue at the sixth potential N-glycosylation site. In at least one embodiment, the rhGAA comprises a sixth potential N- glycosylation site occupancy as depicted in Fig. 6A and an N-glycosylation profile as depicted in Fig. 6G. In at least one embodiment, the rhGAA comprises a sixth potential N-glycosylation site occupancy as depicted in Fig. 32A and an N-glycosylation profile as depicted in Fig. 32G or Fig. 33B.
  • At least 5% of the rhGAA is phosphorylated at the seventh potential N-glycosylation site (e.g., N869 for SEQ ID NO: 6 and N925 for SEQ ID NO: 4). In other embodiments, less than 5%, 10%, 15%, 20%, or 25% of the rhGAA is phosphorylated at the seventh potential N-glycosylation site. In some embodiments, less than 40%, 45%, 50%, 55%, 60%, or 65% of the rhGAA has any N-glycan at the seventh potential N-glycosylation site.
  • the rhGAA has an N-glycan at the seventh potential N-glycosylation site.
  • the rhGAA comprises on average at least 0.5 mol sialic acid per mol rhGAA at the seventh potential N-glycosylation site.
  • the rhGAA comprises on average at least 0.8 mol sialic acid per mol rhGAA at the seventh potential N-glycosylation site.
  • the rhGAA comprises on average about 0.86 mol sialic acid per mol rhGAA at the seventh potential N-glycosylation site.
  • the rhGAA comprises an average of at least 0.3 mol glycan species bearing poly-LacNAc residues per mol rhGAA at the seventh potential N-glycosylation site. In some embodiments, nearly half of the rhGAA comprises a glycan bearing a poly-LacNAc residue at the seventh potential N-glycosylation site. In at least one embodiment, all N-glycans identified at the seventh potential N-glycosylation site are complex N- glycans. In at least one embodiment, the rhGAA comprises a seventh potential N-glycosylation site occupancy as depicted in Fig. 6A or as depicted in Fig. 32A and an N-glycosylation profile as depicted in Fig. 32H or Fig. 33B.
  • the rhGAA comprises on average 3-4 M6P residues per rhGAA molecule and about 4 to about 7.3 mol sialic acid per mol rhGAA.
  • the rhGAA further comprises on average at least about 0.5 mol bis-M6P per mol rhGAA at the first potential N-glycosylation site, about 0.4 to about 0.6 mol mono-M6P per mol rhGAA at the second potential N-glycosylation site, about 0.9 to about 1.2 mol sialic acid per mol rhGAA at the third potential N-glycosylation site, about 0.4 to about 0.6 mol bis-M6P per mol rhGAA at the fourth potential N-glycosylation site, about 0.3 to about 0.4 mol mono-M6P per mol rhGAA at the fourth potential N-glycosylation site, about 0.8 to about 0.9 mol sialic acid per mol r
  • the rhGAA further comprises on average at least 0.5 mol sialic acid per mol rhGAA at the seventh potential N-glycosylation site. In some embodiments, the rhGAA comprises on average at least 0.8 mol sialic acid per mol rhGAA at the seventh potential N-glycosylation site. In at least one embodiment, the rhGAA further comprises on average about 0.86 mol sialic acid per mol rhGAA at the seventh potential N-glycosylation site. In at least one embodiment, the rhGAA comprises seven potential N-glycosylation sites with occupancy and N-glycosylation profdes as depicted in Figs. 6A-6H. In at least one embodiment, the rhGAA comprises seven potential N-glycosylation sites with occupancy and N-glycosylation profdes as depicted in Figs. 32A-32H and Figs. 33A-33B.
  • rhGAA can enzymatically degrade accumulated glycogen.
  • conventional rhGAA products have low total levels of mono-M6P- and bis-M6P bearing N- glycans and, thus, target muscle cells poorly, resulting in inferior delivery of rhGAA to the lysosomes.
  • the majority of rhGAA molecules in these conventional products do not have phosphorylated N- glycans, thereby lacking affinity for the CIMPR.
  • Non-phosphorylated high mannose N-glycans can also be cleared by the mannose receptor, which results in non-productive clearance of the ERT (Fig. 2B).
  • a rhGAA described herein may contains a higher amount of mono-M6P- and bis-M6P bearing N-glycans, leading to productive uptake of rhGAA into specific tissues such as muscle.
  • cells such as Chinese hamster ovary (CHO) cells may be used to produce the rhGAA described therein.
  • CHO Chinese hamster ovary
  • Expressing high M6P rhGAA in CHO cells is advantageous over modifying the glycan profile of an rhGAA post-translationally at least in part because only the former may be converted by glycan degradation to a form of rhGAA with optimal glycogen hydrolysis, thus enhancing therapeutic efficacy.
  • the rhGAA is preferably produced by one or more CHO cell lines that are transformed with a DNA construct encoding the rhGAA described therein.
  • Such CHO cell lines may contain multiple copies of a gene, such as 5, 10, 15, or 20 or more copies, of a polynucleotide encoding GAA.
  • DNA constructs which express allelic variants of acid a-glucosidase or other variant acid a-glucosidase amino acid sequences such as those that are at least 90%, 95%, 98%, or 99% identical to SEQ ID NO: 4 or SEQ ID NO: 6, may be constructed and expressed in CHO cells.
  • Those of skill in the art may select alternative vectors suitable for transforming CHO cells for production of such DNA constructs.
  • the selected CHO cell lines may be used to produce rhGAA and rhGAA compositions by culturing the CHO cell line and recovering said composition from the culture of CHO cells.
  • a rhGAA produced from the selected CHO cell lines contains a high content of N- glycans bearing mono-M6P or bis-M6P that target the CIMPR.
  • a rhGAA produced as described herein has low levels of complex N-glycans with terminal galactose.
  • the selected CHO cell lines are referred to as GA-ATB200 or ATB200-X5-14.
  • the selected CHO cell lines encompass a subculture or derivative of such a CHO cell culture.
  • a rhGAA produced from the selected CHO cell lines is referred to as ATB200.
  • a rhGAA produced as described herein may be purified by following methods described in International Application PCT/US2017/024981 and in U.S. Provisional Application No. 62/506,569, both of which are incorporated herein by reference in their entirety.
  • An exemplary process for producing, capturing, and purifying a rhGAA produced from CHO cell lines is shown in Fig. 3.
  • bioreactor 601 contains a culture of cells, such as CHO cells, that express and secrete rhGAA into the surrounding liquid culture media.
  • the bioreactor 601 may be any appropriate bioreactor for culturing the cells, such as a perfusion, batch or fed-batch bioreactor.
  • the culture media is removed from the bioreactor after a sufficient period of time for cells to produce rhGAA. Such media removal may be continuous for a perfusion bioreactor or may be batch-wise for a batch or fed-batch reactor.
  • the media may be filtered by filtration system 603 to remove cells.
  • Filtration system 603 may be any suitable filtration system, including an alternating tangential flow filtration (ATF) system, a tangential flow filtration (TFF) system, and/or centrifugal filtration system.
  • ATF alternating tangential flow filtration
  • TFF tangential flow filtration
  • centrifugal filtration system utilizes a filter having a pore size between about 10 nanometers and about 2 micrometers.
  • the protein capturing system 605 may include one or more chromatography columns. If more than one chromatography column is used, then the columns may be placed in series so that the next column can begin loading once the first column is loaded. Alternatively, the media removal process can be stopped during the time that the columns are switched.
  • the protein capturing system 605 includes one or more anion exchange (AEX) columns for the direct product capture of rhGAA, particularly rhGAA having a high M6P content.
  • AEX anion exchange
  • the rhGAA captured by the protein capturing system 605 is eluted from the column(s) by changing the pH and/or salt content in the column.
  • Exemplary conditions for an AEX column are provided in Table 2.
  • the eluted rhGAA can be subjected to further purification steps and/or quality assurance steps.
  • the eluted rhGAA may be subjected to a virus kill step 607.
  • a virus kill 607 may include one or more of a low pH kill, a detergent kill, or other technique known in the art.
  • the rhGAA from the virus kill step 607 may be introduced into a second chromatography system 609 to further purify the rhGAA product.
  • the eluted rhGAA from the protein capturing system 605 may be fed directly to the second chromatography system 609.
  • the second chromatography system 609 includes one or more immobilized metal affinity chromatography (IMAC) columns for further removal of impurities. Exemplary conditions for an IMAC column are provided in Table 3 below.
  • virus kill 611 may include one or more of a low pH kill, a detergent kill, or other technique known in the art. In some embodiments, only one of virus kill 607 or 611 is used, or the virus kills are performed at the same stage in the purification process.
  • the rhGAA from the virus kill step 611 may be introduced into a third
  • the third chromatography system 613 includes one or more cation exchange chromatography (CEX) columns and/or size exclusion chromatography (SEC) columns for further removal of impurities.
  • CEX cation exchange chromatography
  • SEC size exclusion chromatography
  • the rhGAA product may also be subjected to further processing.
  • another fdtration system 615 may be used to remove viruses.
  • such filtration can utilize filters with pore sizes between 5 and 50 pm.
  • Other product processing can include a product adjustment step 617, in which the recombinant protein product may be sterilized, filtered, concentrated, stored, and/or have additional components for added for the final product formulation.
  • ATB200 refers to a rhGAA with a high content of N- glycans bearing mono-M6P and bis-M6P, which is produced from a GA-ATB200 cell line and purified using methods described herein.
  • a pharmaceutical composition comprising the rhGAA described herein, either alone or in combination with other therapeutic agents, and/or a
  • a pharmaceutical composition described herein comprises a pharmaceutically acceptable salt.
  • the pharmaceutically acceptable salt used herein is a pharmaceutically-acceptable acid addition salt.
  • the pharmaceutically-acceptable acid addition salt may include, but is not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, phosphoric acid, and the like, and organic acids including but not limited to acetic acid, trifluoroacetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, butyric acid, camphoric acid, camphorsulfonic acid, cinnamic acid, citric acid, digluconic acid, ethanesulfonic acid, glutamic acid, glycolic acid, glycerophosphoric acid, hemisulfic acid, hexanoic acid, formic acid, fumaric acid, 2-hydroxyethanesulfonic acid (isethionic acid), lactic acid, hydroxymaleic acid, malic acid,
  • methane sulfonic acid methane sulfonic acid, naphthalenesulfonic acid, nicotinic acid, 2-naphthalenesulfonic acid, oxalic acid, pamoic acid, pectinic acid, phenylacetic acid, 3-phenylpropionic acid, pivalic acid, propionic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, p- toluenesulfonic acid, undecanoic acid, and the like.
  • the pharmaceutically acceptable salt used herein is a pharmaceutically-acceptable base addition salt.
  • the pharmaceutically-acceptable base addition salt may include, but is not limited to, ammonia or the hydroxide, carbonate, or bicarbonate of ammonium or a metal cation such as sodium, potassium, lithium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like.
  • Salts derived from pharmaceutically-acceptable organic nontoxic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, quaternary amine compounds, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion-exchange resins, such as methylamine, dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine, isopropylamine, tripropylamine, tributylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine,
  • tetramethylammonium compounds tetraethylammonium compounds
  • pyridine N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, dibenzylamine, N,N- dibenzylphenethylamine, 1-ephenamine, N,N'- dibenzylethylenediamine, polyamine resins, and the like.
  • the rhGAA or a pharmaceutically acceptable salt thereof may be formulated as a pharmaceutical composition adapted for intravenous administration.
  • the pharmaceutical composition is a solution in sterile isotonic aqueous buffer.
  • the composition may also include a solubilizing agent and a local anesthetic to ease pain at the site of the injection.
  • the ingredients of the pharmaceutical composition may be supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampule or sachet indicating the quantity of active agent.
  • composition may be administered by infusion, it may be dispensed with an infusion bottle containing sterile pharmaceutical grade water, saline or dextrose/water.
  • the infusion may occur at a hospital or clinic. In some embodiments, the infusion may occur outside the hospital or clinic setting, for example, at a subject’s residence.
  • an ampule of sterile water for injection or saline may be provided so that the ingredients may be mixed prior to administration.
  • the rhGAA or a pharmaceutically acceptable salt thereof may be formulated for oral administration.
  • Orally administrable compositions may be formulated in a form of tablets, capsules, ovules, elixirs, solutions or suspensions, gels, syrups, mouth washes, or a dry powder for reconstitution with water or other suitable vehicle before use, optionally with flavoring and coloring agents for immediate-, delayed-, modified-, sustained-, pulsed-, or controlled-release applications.
  • Solid compositions such as tablets, capsules, lozenges, pastilles, pills, boluses, powder, pastes, granules, bullets, dragees, or premix preparations can also be used.
  • compositions for oral use may be prepared according to methods well known in the art. Such compositions can also contain one or more pharmaceutically acceptable carriers and excipients which can be in solid or liquid form. Tablets or capsules can be prepared by conventional means with pharmaceutically acceptable excipients, including but not limited to binding agents, fillers, lubricants, disintegrants, or wetting agents. Suitable pharmaceutically acceptable excipients are known in the art and include but are not limited to pregelatinized starch, polyvinylpyrrolidone, povidone,
  • hydroxypropyl methylcellulose HPMC
  • HPEC hydroxypropyl ethylcellulose
  • HPPC hydroxypropyl cellulose
  • sucrose gelatin, acacia, lactose, microcrystalline cellulose, calcium hydrogen phosphate, magnesium stearate, stearic acid, glyceryl behenate, talc, silica, com, potato or tapioca starch, sodium starch glycolate, sodium lauryl sulfate, sodium citrate, calcium carbonate, dibasic calcium phosphate, glycine croscarmellose sodium, and complex silicates. Tablets can be coated by methods well known in the art.
  • a pharmaceutical composition described herein may be formulated according to International Application PCT/US2017/024982 and U.S. Provisional Application No. 62/506,574, both incorporated herein by reference in their entirety.
  • the pH of a pharmaceutical composition described herein is from about 5.0 to about 7.0 or about 5.0 to about 6.0. In some embodiments, the pH ranges from about 5.5 to about 6.0. In some embodiments, the pH of the pharmaceutical composition is 6.0. In some embodiments, the pH may be adjusted to a target pH by using pH adjusters (e.g., alkalizing agents and acidifying agents) such as sodium hydroxide and/or hydrochloric acid.
  • pH adjusters e.g., alkalizing agents and acidifying agents
  • the pharmaceutical composition described herein may comprise a buffer system such as a citrate system, a phosphate system, and a combination thereof.
  • the citrate and/or phosphate may be a sodium citrate or sodium phosphate.
  • Other salts include potassium and ammonium salts.
  • the buffer comprises a citrate.
  • the buffer comprises sodium citrate (e.g., a mixture of sodium citrate dehydrate and citric acid monohydrate).
  • buffer solutions comprising a citrate may comprise sodium citrate and citric acid.
  • both a citrate and phosphate buffer are present.
  • a pharmaceutical composition described herein comprises at least one excipient.
  • the excipient may function as a tonicity agent, bulking agent, and/or stabilizer.
  • Tonicity agents are components which help to ensure the formulation has an osmotic pressure similar to or the same as human blood.
  • Bulking agents are ingredients which add mass to the formulations (e.g. lyophilized) and provide an adequate structure to the cake.
  • Stabilizers are compounds that can prevent or minimize the aggregate formation at the hydrophobic air-water interfacial surfaces.
  • One excipient may function as a tonicity agent and bulking agent at the same time. For instance, mannitol may function as a tonicity agent and also provide benefits as a bulking agent.
  • tonicity agents include sodium chloride, mannitol, sucrose, and trehalose.
  • the tonicity agent comprises mannitol.
  • the total amount of tonicity agent(s) ranges in an amount of from about 10 mg/mL to about 50 mg/mL. In further embodiments, the total amount of tonicity agent(s) ranges in an amount of from about 10, 11, 12, 13, 14, or 15 mg/mL to about 16, 20, 25, 30, 35, 40, 45, or 50 mg/mL.
  • the excipient comprises a stabilizer.
  • the stabilizer is a surfactant.
  • the stabilizer is polysorbate 80.
  • the total amount of stabilizer ranges from about 0.1 mg/mL to about 1.0 mg/mL. In further embodiments, the total amount of stabilizer ranges from about 0.1, 0.2, 0.3, 0.4, or 0.5 mg/mL to about 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 mg/mL. In yet further embodiments, the total amount of stabilizer is about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 mg/mL.
  • a pharmaceutical composition comprises (a) a rhGAA (such as ATB200), (b) at least one buffer selected from the group consisting of a citrate, a phosphate, and a combination thereof, and (c) at least one excipient selected from the group consisting of mannitol, polysorbate 80, and a combination thereof, and has a pH of (i) from about 5.0 to about 6.0, or (ii) from about 5.0 to about 7.0.
  • the composition further comprises water.
  • the composition may further comprise an acidifying agent and/or alkalizing agent.
  • the pharmaceutical composition comprises (a) a rhGAA (such as ATB200) at a concentration of about 5-50 mg/mL, about 5-30 mg/mL, or about 15 mg/mL, (b) sodium citrate buffer at a concentration of about 10-100 mM or about 25 mM, (c) mannitol at a concentration of about 10-50 mg/mL, or about 20 mg/mL, (d) polysorbate 80, present at a concentration of about 0.1-1 mg/mL, about 0.2-0.5 mg/mL, or about 0.5 mg/mL, and (e) water, and has a pH of about 6.0.
  • a rhGAA such as ATB200
  • the pharmaceutical composition comprises (a) 15 mg/mL rhGAA (such as ATB200) (b) 25 mM sodium citrate buffer, (c) 20 mg/mL mannitol (d) 0.5 mg/mL polysorbate 80, and (e) water, and has a pH of about 6.0.
  • the composition may further comprise an acidifying agent and/or alkalizing agent.
  • the pharmaceutical composition comprising rhGAA is diluted prior to administration to a subject in need thereof.
  • a pharmaceutical composition described herein comprises a chaperone.
  • the chaperone is miglustat or a pharmaceutically acceptable salt thereof.
  • the chaperone is duvoglustat or a pharmaceutically acceptable salt thereof.
  • a rhGAA described herein is formulated in one pharmaceutical composition while a chaperone such as miglustat is formulated in another pharmaceutical
  • the pharmaceutical composition comprising miglustat is based on a formulation available commercially as Zavesca® (Actelion Pharmaceuticals).
  • the pharmaceutical composition described herein may undergo lyophilization (freeze-drying) process to provide a cake or powder.
  • a pharmaceutical composition after lyophilization may comprise the rhGAA described herein (e.g., ATB200), buffer selected from the group consisting of a citrate, a phosphate, and combinations thereof, and at least one excipient selected from the group consisting of trehalose, mannitol, polysorbate 80, and a combination thereof.
  • other ingredients e.g., other excipients
  • composition comprising the lyophilized formulation may be provided vial, which then can be stored, transported, reconstituted and/or administered to a patient.
  • Another aspect of the invention pertains to a method of treatment of a disease or disorder related to glycogen storage dysregulation by administering the rhGAA or pharmaceutical composition described herein.
  • the disease is Pompe disease (also known as acid maltase deficiency (AMD) and glycogen storage disease type II (GSD II)).
  • Pompe disease also known as acid maltase deficiency (AMD) and glycogen storage disease type II (GSD II)
  • AMD acid maltase deficiency
  • GSD II glycogen storage disease type II
  • the rhGAA is ATB200.
  • the pharmaceutical composition comprises ATB200.
  • the rhGAA or pharmaceutical composition described herein is administered by an appropriate route.
  • the rhGAA or pharmaceutical composition is administered intravenously.
  • the rhGAA or pharmaceutical composition is administered by direct administration to a target tissue, such as to heart or skeletal muscle (e.g., intramuscular), or nervous system (e.g., direct injection into the brain; intraventricularly; intrathecally).
  • a target tissue such as to heart or skeletal muscle (e.g., intramuscular), or nervous system (e.g., direct injection into the brain; intraventricularly; intrathecally).
  • the rhGAA or pharmaceutical composition is administered orally. More than one route can be used concurrently, if desired.
  • the therapeutic effects of the rhGAA or pharmaceutical composition described herein may be assessed based on one or more of the following criteria: (1) cardiac status (e.g.
  • the cardiac status of a subject is improved by 10%, 20%, 30%, 40%, or 50% (or any percentage in-between) after administration of one or more dosages of the rhGAA or pharmaceutical composition described herein, as compared to that of a subject treated with a vehicle or that of a subject prior to treatment.
  • the cardiac status of a subject may be assessed by measuring end-diastolic and/or end-systolic volumes and/or by clinically evaluating cardiomyopathy.
  • the pulmonary function of a subject is improved by 10%, 20%, 30%, 40%, or 50% (or any percentage in-between) after administration of one or more dosages of ATB200 or pharmaceutical composition comprising ATB200, as compared to that of a subject treated with a vehicle or that of a subject prior to treatment.
  • the improvement is achieved after 1 week, 2 weeks, 3 weeks, 1 month, 2 months, or more from administration (or any time period in between).
  • ATB200 or pharmaceutical composition comprising ATB200 improves the pulmonary function of a subject after 1 week, 2 weeks, 3 weeks, 1 month, 2 months, or more from administration (or any time period in between).
  • the pulmonary function of a subject is improved by 10%, 20%, 30%, 40%, or 50% (or any percentage in-between) after administration of one or more dosages of the rhGAA or pharmaceutical composition described herein, as compared to that of a subject treated with a vehicle or that of a subject prior to treatment.
  • the pulmonary function of a subject may be assessed by crying vital capacity over baseline capacity, and/or normalization of oxygen desaturation during crying.
  • the pulmonary function of a subject is improved by 10%, 20%, 30%, 40%, or 50% (or any percentage in-between) after administration of one or more dosages of ATB200 or pharmaceutical composition comprising ATB200, as compared to that of a subject treated with a vehicle or that of a subject prior to treatment.
  • the improvement is achieved after 1 week, 2 weeks, 3 weeks, 1 month, 2 months, or more from administration (or any time period in between).
  • ATB200 or pharmaceutical composition comprising ATB200 improves the pulmonary function of a subject after 1 week, 2 weeks, 3 weeks, 1 month, 2 months, or more from administration (or any time period in between).
  • the neurodevelopment and/or motor skills of a subject is improved by 10%, 20%, 30%, 40%, or 50% (or any percentage in-between) after administration of one or more dosages of the rhGAA or pharmaceutical composition described herein, as compared to that of a subject treated with a vehicle or that of a subject prior to treatment.
  • the neurodevelopment and/or motor skills of a subject may be assessed by determining an AIMS score.
  • the AIMS is a 12- item anchored scale that is clinician-administered and scored (see Rush JA Jr., Handbook of
  • Items 1-10 are rated on a 5-point anchored scale. Items 1-4 assess orofacial movements. Items 5-7 deal with extremity and truncal dyskinesia. Items 8-10 deal with global severity as judged by the examiner, and the patient’s awareness of the movements and the distress associated with them. Items 11-12 are yes/no questions concerning problems with teeth and/or dentures (such problems can lead to a mistaken diagnosis of dyskinesia).
  • the neurodevelopment and/or motor skills of a subject is improved by 10%, 20%, 30%, 40%, or 50% (or any percentage in-between) after administration of one or more dosages of ATB200 or pharmaceutical composition comprising ATB200, as compared to that of a subject treated with a vehicle or that of a subject prior to treatment.
  • the improvement is achieved after 1 week, 2 weeks, 3 weeks, 1 month, 2 months, or more from administration (or any time period in between).
  • ATB200 or pharmaceutical composition comprising ATB200 improves the neurodevelopment and/or motor skills of a subject after 1 week, 2 weeks, 3 weeks, 1 month, 2 months, or more from administration (or any time period in between).
  • the glycogen level of a certain tissue of a subject is reduced by 10%, 20%, 30%, 40%, or 50% (or any percentage in-between) after administration of one or more dosages of the rhGAA or pharmaceutical composition described herein, as compared to that of a subject treated with a vehicle or that of a subject prior to treatment.
  • the tissue is muscle such as quadriceps, triceps, and gastrocnemius.
  • the glycogen level of a tissue can be analyzed using methods known in the art. The determination of glycogen levels is well known based on amyloglucosidase digestion, and is described in publications such as: Amalfitano et al.
  • the glycogen level in muscle of a subject is reduced by 10%, 20%, 30%, 40%, or 50% (or any percentage in between) after administration of one or more dosages of ATB200 or pharmaceutical composition comprising ATB200, as compared to that of a subject treated with a vehicle or that of a subject prior to treatment.
  • the reduction is achieved after 1 week, 2 weeks, 3 weeks, 1 month, 2 months, or more from administration (or any time period in between).
  • ATB200 or pharmaceutical composition comprising ATB200 reduces the glycogen level in muscle of a subject after 1 week, 2 weeks, 3 weeks, 1 month, 2 months, or more from administration (or any time period in between).
  • Biomarkers of glycogen accumulation in a muscle fiber in a subject such as urine hexose tetrasaccharide (Hex4), may be used to assess and compare the therapeutic effects of enzyme replacement therapy in a subject with Pompe disease.
  • the therapeutic effect of the rhGAA or a pharmaceutical composition comprising rhGAA on glycogen accumulation is assessed by measuring the levels of Hex4 in a subject.
  • Biomarkers of muscle injury or damage such as creatine kinase (CK), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) may be used to assess and compare the therapeutic effects of enzyme replacement therapy in a subject with Pompe disease.
  • the therapeutic effect of the rhGAA or a pharmaceutical composition comprising rhGAA on muscle damage is assessed by measuring the levels of CK, ALT, and/or AST in a subject.
  • the therapeutic effect of the rhGAA or a pharmaceutical composition comprising rhGAA on muscle damage is assessed by measuring the levels of CK in a subject.
  • Biomarkers such as LAMP-1, LC3, and Dysferlin may also be used to assess and compare the therapeutic effects of the rhGAA or pharmaceutical composition described herein.
  • Pompe disease the failure of GAA to hydrolyze lysosomal glycogen leads to the abnormal accumulation of large lysosomes filled with glycogen in some tissues.
  • Studies in a mouse model of Pompe disease have shown that the enlarged lysosomes in skeletal muscle cannot adequately account for the reduction in mechanical performance, and that the presence of large inclusions containing degraded myofibrils (i.e., autophagic buildup) contributes to the impairment of muscle function.
  • a sample from a subject treated with the rhGAA or pharmaceutical composition described herein can be obtained, such as biopsy of tissues, in particular muscle.
  • the sample is a biopsy of muscle in a subject.
  • the muscle is selected from quadriceps, triceps, and gastrocnemius.
  • the sample obtained from a subject may be stained with one or more antibodies or other detection agents that detect such biomarkers or be identified and quantified by mass spectrometry.
  • the samples may also or alternatively be processed for detecting the presence of nucleic acids, such as mRNAs, encoding the biomarkers via, e.g., RT-qPCR methods.
  • the gene expression level and/or protein level of one or more biomarkers is measured in a muscle biopsy obtained from an individual prior to and post treatment with the rhGAA or pharmaceutical composition described herein.
  • the gene expression level and/or protein level of one or more biomarkers is measured in a muscle biopsy obtained from an individual treated with a vehicle.
  • the gene expression level and/or protein level of one or more biomarkers is reduced by 10%, 20%, 30%, 40%, or 50% (or any percentage in-between) after administration of one or more dosages of the rhGAA or pharmaceutical composition described herein, as compared to that of a subject treated with a vehicle or that of a subject prior to treatment. In some embodiments, the gene expression level and/or protein level of one or more biomarkers is reduced by 10%, 20%, 30%, 40%, or 50% (or any percentage in-between) after administration of one or more dosages of ATB200 or pharmaceutical composition comprising ATB200, as compared to that of a subject treated with a vehicle or that of a subject prior to treatment.
  • the reduction is achieved after 1 week, 2 weeks, 3 weeks, 1 month, 2 months, or more from administration (or any time period in between).
  • ATB200 or pharmaceutical composition comprising ATB200 reduces the gene expression level and/or protein level of one or more biomarkers after 1 week, 2 weeks, 3 weeks, 1 month, 2 months, or more from administration (or any time period in between).
  • the pharmaceutical formulation or reconstituted composition is administered in a therapeutically effective amount (e.g., a dosage amount that, when administered at regular intervals, is sufficient to treat the disease, such as by ameliorating symptoms associated with the disease, preventing or delaying the onset of the disease, and/or lessening the severity or frequency of symptoms of the disease).
  • a therapeutically effective amount e.g., a dosage amount that, when administered at regular intervals, is sufficient to treat the disease, such as by ameliorating symptoms associated with the disease, preventing or delaying the onset of the disease, and/or lessening the severity or frequency of symptoms of the disease.
  • the amount which is therapeutically effective in the treatment of the disease may depend on the nature and extent of the disease's effects, and can be determined by standard clinical techniques.
  • in vitro or in vivo assays may optionally be employed to help identify optimal dosage ranges.
  • a rhGAA described herein or pharmaceutical composition comprising the rhGAA is administered at a dose of about 1 mg/kg to about 100 mg/kg, such as about 5 mg/kg to about 30 mg/kg, typically about 5 mg/kg to about 20 mg/kg.
  • the rhGAA or pharmaceutical composition described herein is administered at a dose of about 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 50 mg/kg, about 50 mg/kg, about 60 mg/kg, about 70 mg/kg, about 80 mg/kg, about 90 mg/kg, or about 100 mg/kg.
  • a rhGAA described herein or pharmaceutical composition comprising the rhGAA is administered at a dose of about 1 mg/kg to about 100 mg/kg, such as about 5 mg/kg to about 30 mg/kg, typically about 5 mg/kg to about 20 mg/kg.
  • the rhGAA is administered at a dose of 5 mg/kg, 10 mg/kg, 20 mg/kg, 50 mg/kg, 75 mg/kg, or 100 mg/kg. In at least one embodiment, the rhGAA or pharmaceutical composition is administered at a dose of about 20 mg/kg. In some embodiments, the rhGAA or pharmaceutical composition is administered concurrently or sequentially with a pharmacological chaperone. In some embodiments, the pharmacological chaperone is miglustat. In at least one embodiment, the miglustat is administered as an oral dose of about 260 mg.
  • the effective dose for a particular individual can be varied (e.g. increased or decreased) over time, depending on the needs of the individual. For example, in times of physical illness or stress, or if anti-acid a-glucosidase antibodies become present or increase, or if disease symptoms worsen, the amount of rhGAA and/or miglustat can be adjusted.
  • the therapeutically effective dose of the rhGAA or pharmaceutical composition described herein is lower than that of conventional rhGAA products. For instance, if the therapeutically effective dose of a conventional rhGAA product is 20 mg/kg, the dose of the rhGAA or pharmaceutical composition described herein required to produce the same as or better therapeutic effects than the conventional rhGAA product may be lower than 20 mg/kg.
  • Therapeutic effects may be assessed based on one or more criteria discussed above (e.g., cardiac status, glycogen level, or biomarker expression).
  • the therapeutically effective dose of the rhGAA or pharmaceutical composition described herein is at least about 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or more lower than that of conventional rhGAA products.
  • the therapeutic effect of the rhGAA or pharmaceutical composition described herein comprises an improvement in motor function, an improvement in muscle strength (upper-body, lower-body, or total-body), an improvement in pulmonary function, decreased fatigue, reduced levels of at least one biomarker of muscle injury, reduced levels of at least one biomarker of glycogen accumulation, or a combination thereof.
  • the therapeutic effect of the rhGAA or pharmaceutical composition described herein comprises a reversal of lysosomal pathology in a muscle fiber, a faster and/or more effective reduction in glycogen content in a muscle fiber, an increase in six-minute walk test distance, a decrease in timed up and go test time, a decrease in four-stair climb test time, a decrease in ten-meter walk test time, a decrease in gait-stair- gower-chair score, an increase in upper extremity strength, an improvement in shoulder adduction, an improvement in shoulder abduction, an improvement in elbow flexion, an improvement in elbow extension, an improvement in upper body strength, an improvement in lower body strength, an improvement in total body strength, an improvement in upright (sitting) forced vital capacity, an improvement in maximum expiratory pressure, an improvement in maximum inspiratory pressure, a decrease in fatigue severity scale score, a reduction in urine hexose tetrasaccharide levels, a reduction in creatine kinase levels, a
  • the rhGAA or pharmaceutical composition described herein achieves desired therapeutic effects faster than conventional rhGAA products when administered at the same dose.
  • Therapeutic effects may be assessed based on one or more criteria discussed above (e.g., cardiac status, glycogen level, or biomarker expression). For instance, if a single dose of a conventional rhGAA product decreases glycogen levels in tissue of a treated individual by 10% in a week, the same degree of reduction may be achieved in less than a week when the same dose of the rhGAA or pharmaceutical composition described herein is administered.
  • the rhGAA or pharmaceutical composition described herein may achieves desired therapeutic effects at least about 1.25, 1.5, 1.75, 2.0, 3.0, or more faster than conventional rhGAA products.
  • the therapeutically effective amount of rhGAA (or composition or medicament comprising rhGAA) is administered more than once.
  • the rhGAA or pharmaceutical composition described herein is administered at regular intervals, depending on the nature and extent of the disease's effects, and on an ongoing basis.
  • Administration at a“regular interval,” as used herein, indicates that the therapeutically effective amount is administered periodically (as distinguished from a one-time dose).
  • the interval can be determined by standard clinical techniques.
  • rhGAA is administered bimonthly, monthly, bi-weekly, weekly, twice weekly, or daily.
  • the rhGAA is administered intravenously twice weekly, weekly, or every other week.
  • the administration interval for a single individual need not be a fixed interval, but can be varied over time, depending on the needs of the individual. For example, in times of physical illness or stress, if anti -rhGAA antibodies become present or increase, or if disease symptoms worsen, the interval between doses can be decreased.
  • the rhGAA or pharmaceutical composition as described herein when used at the same dose, may be administered less frequently than conventional rhGAA products and yet capable of producing the same as or better therapeutic effects than conventional rhGAA products. For instance, if a conventional rhGAA product is administered at 20 mg/kg weekly, the rhGAA or pharmaceutical composition as described herein may produce the same as or better therapeutic effects than the conventional rhGAA product when administered at 20 mg/kg, even though the rhGAA or pharmaceutical composition is administered less frequently, e.g., biweekly or monthly. Therapeutic effects may be assessed based on one or more criterion discussed above (e.g., cardiac status, glycogen level, or biomarker expression).
  • an interval between two doses of the rhGAA or pharmaceutical composition described herein is longer than that of conventional rhGAA products. In some embodiments, the interval between two doses of the rhGAA or pharmaceutical composition is at least about 1.25, 1.5, 1.75, 2.0, 3.0, or more longer than that of conventional rhGAA products.
  • the rhGAA or pharmaceutical composition described herein provides therapeutic effects at a degree superior than that provided by conventional rhGAA products. Therapeutic effects may be assessed based on one or more criteria discussed above (e.g., cardiac status, glycogen level, or biomarker expression). For instance, when compared to a conventional rhGAA product administered at 20 mg/kg weekly, the rhGAA or pharmaceutical composition administered at 20 mg/kg weekly may reduce glycogen levels in tissue of a treated individual at a higher degree. In some embodiments, when administered under the same treatment condition, the rhGAA or pharmaceutical composition described herein provides therapeutic effects that are at least about 1.25, 1.5, 1.75, 2.0, 3.0, or more greater than those of conventional rhGAA products.
  • the rhGAA or pharmaceutical composition comprising the rhGAA described herein is administered concurrently or sequentially with a pharmacological chaperone.
  • the rhGAA or pharmaceutical composition is administered via a different route as compared to the pharmacological chaperone.
  • a pharmacological chaperone may be administered orally while the rhGAA or pharmaceutical composition is administered intravenously.
  • the pharmacological chaperone is miglustat.
  • the miglustat is administered at an oral dose of about 50 mg to about 600 mg.
  • the miglustat is administered at an oral dose of about 200 mg to about 600 mg, or at an oral dose of about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, or about 600 mg.
  • the miglustat is administered at an oral dose of about 233 mg to about 500 mg.
  • the miglustat is administered at an oral dose of about 250 to about 270 mg, or at an oral dose of about 250 mg, about 255 mg, about 260 mg, about 265 mg or about 270 mg. In at least one embodiment, the miglustat is administered as an oral dose of about 260 mg.
  • an oral dose of miglustat in the range of about 200 mg to 600 mg or any smaller range therewith can be suitable for an adult patient depending on his/her body weight. For instance, for patients having a significantly lower body weight than about 70 kg, including but not limited to infants, children, or underweight adults, a smaller dose may be considered suitable by a physician. Therefore, in at least one embodiment, the miglustat is administered as an oral dose of from about 50 mg to about 200 mg, or as an oral dose of about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 130 mg, about 150 mg, about 175 mg, about 200 mg, or about 260 mg. In at least one embodiment, the miglustat is administered as an oral dose of from about 65 mg to about 195 mg, or as an oral dose of about 65 mg, about 130 mg, or about 195 mg.
  • the rhGAA is administered intravenously at a dose of about 5 mg/kg to about 20 mg/kg and the miglustat is administered orally at a dose of about 50 mg to about 600 mg. In some embodiments, the rhGAA is administered intravenously at a dose of about 5 mg/kg to about 20 mg/kg and the miglustat is administered orally at a dose of about 50 mg to about 200 mg. In some embodiments, the rhGAA is administered intravenously at a dose of about 5 mg/kg to about 20 mg/kg and the miglustat is administered orally at a dose of about 200 mg to about 600 mg.
  • the rhGAA is administered intravenously at a dose of about 5 mg/kg to about 20 mg/kg and the miglustat is administered orally at a dose of about 233 mg to about 500 mg. In one embodiment, the rhGAA is administered intravenously at a dose of about 20 mg/kg and the miglustat is administered orally at a dose of about 260 mg.
  • the miglustat and the rhGAA are administered concurrently.
  • the miglustat may administered within 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 minute(s) before or after administration of the rhGAA.
  • the miglustat is administered within 5, 4, 3, 2, or 1 minute(s) before or after administration of the rhGAA.
  • the miglustat and the rhGAA are administered sequentially. In at least one embodiment, the miglustat is administered prior to administration of the rhGAA. In at least one embodiment, the miglustat is administered less than three hours prior to administration of the rhGAA. In at least one embodiment, the miglustat is administered about two hours prior to administration of the rhGAA. For instance, the miglustat may be administered about 1.5 hours, about 1 hour, about 50 minutes, about 30 minutes, or about 20 minutes prior to administration of the rhGAA. In at least one embodiment, the miglustat is administered about one hour prior to administration of the rhGAA.
  • the miglustat is administered after administration of the rhGAA. In at least one embodiment, the miglustat is administered within three hours after administration of the rhGAA. In at least one embodiment, the miglustat is administered within two hours after administration of the rhGAA. For instance, the miglustat may be administered within about 1.5 hours, about 1 hour, about 50 minutes, about 30 minutes, or about 20 minutes after administration of the rhGAA.
  • the subject fasts for at least two hours before and at least two hours after administration of miglustat.
  • kits comprising the rhGAA or pharmaceutical composition described herein.
  • the kit comprises a container (e.g., vial, tube, bag, etc.) comprising the rhGAA or pharmaceutical composition (either before or after lyophilization) and instructions for reconstitution, dilution and administration.
  • Example 1 Preparation of CHO Cells producing rhGAA having a high content of mono- or bis- M6P-bearing N-glycans.
  • DG44 CHO (DHFR-) cells were transfected with a DNA construct that expresses rhGAA.
  • the DNA construct is shown in Fig. 4.
  • CHO cells containing a stably integrated GAA gene were selected with hypoxanthine/thymidine deficient (-HT) medium).
  • MTX methotrexate treatment
  • ATB200 rhGAA was analyzed for site-specific N-glycan profiles using different LC- MS/MS analytical techniques.
  • the results of the first two LC-MS/MS methods are shown in Figs. 6A-6H.
  • the results of a third LC-MS/MS method with 2-AA glycan mapping is shown in Figs. 32A- 32H, Fig. 33A-33B, and Table 5.
  • the protein was denatured, reduced, alkylated, and digested prior to LC-MS/MS analysis.
  • 200 pg of protein sample 5 pL of 1 mol/L tris-HCl (final concentration 50 mM), 75 pL of 8 mol/L guanidine HC1 (final concentration 6 M), 1 pL of 0.5 mol/L EDTA (final concentration 5 mM), 2 pL of 1 mol/L DTT (final concentration 20 mM), and Milli-Q® water were added to a 1.5 mL tube to provide a total volume of 100 pL.
  • the sample was mixed and incubated at 56°C for 30 minutes in a dry bath.
  • the denatured and reduced protein sample was mixed with 5 pL of 1 mol/L iodoacetamide (IAM, final concentration 50 mM), then incubated at 10-30°C in the dark for 30 minutes.
  • IAM 1 mol/L iodoacetamide
  • 400 pL of precooled acetone was added to the sample and the mixture was frozen at -80°C refrigeration for 4 hours.
  • the sample was then centrifuged for 5 min at 13000 rpm at 4°C and the supernatant was removed.
  • the ATB200 sample was prepared according to a similar denaturation, reduction, alkylation, and digestion procedure, except that iodoacetic acid (IAA) was used as the alkylation reagent instead of IAM, and then analyzed using the Thermo ScientificTM Orbitrap FusionTM Lumos TribidTM Mass Spectrometer.
  • IAA iodoacetic acid
  • Figs. 6A-6H The results of the first and second analyses are shown in Figs. 6A-6H.
  • the results of the first analysis are represented by left bar (dark grey) and the results from the second analysis are represented by the right bar (light grey).
  • the symbol nomenclature for glycan representation is in accordance with Varki, A., Cummings, R.D., Esko J.D., et ah, Essentials of Gly cobiology, 2nd edition (2009).
  • the total number of non-phosphorylated N-glycans may be underrepresented, and the percentage of rhGAA bearing the phosphorylated N-glycans at that site may be overrepresented.
  • Fig. 6A shows the N-glycosylation site occupancy of ATB200.
  • the first, second, third, fourth, fifth, and sixth N-glycosylation sites are mostly occupied, with both analyses detecting around or over 90% and up to about 100% of the ATB200 enzyme having an N-glycan detected at each potential N-glycosylation site.
  • the seventh potential N- glycosylation site is N-glycosylated about half of the time.
  • Fig. 6B shows the N-glycosylation profile of the first potential N-glycosylation site, N84.
  • the major N-glycan species is bis-M6P N-glycans.
  • Both the first and second analyses detected over 75% of the ATB200 having bis-M6P at the first site, corresponding to an average of about 0.8 mol bis-M6P per mol ATB200 at the first site.
  • Fig. 6C shows the N-glycosylation profile of the second potential N-glycosylation site, N177.
  • the major N-glycan species are mono-M6P N-glycans and non-phosphorylated high mannose N-glycans.
  • Both the first and second analyses detected over 40% of the ATB200 having mono-M6P at the second site, corresponding to an average of about 0.4 to about 0.6 mol mono-M6P per mol ATB200 at the second site.
  • Fig. 6D shows the N-glycosylation profile of the third potential N-glycosylation site, N334.
  • the major N-glycan species are non-phosphorylated high mannose N-glycans, di-, tri-, and tetra-antennary complex N-glycans, and hybrid N-glycans.
  • Both the first and second analyses detected over 20% of the ATB200 having a sialic acid residue at the third site, corresponding to an average of about 0.9 to about 1.2 mol sialic acid per mol ATB200 at the third site.
  • Fig. 6E shows the N-glycosylation profile of the fourth potential N-glycosylation site, N414.
  • the major N-glycan species are bis-M6P and mono-M6P N- glycans.
  • Both the first and second analyses detected over 40% of the ATB200 having bis-M6P at the fourth site, corresponding to an average of about 0.4 to about 0.6 mol bis-M6P per mol ATB200 at the fourth site.
  • Both the first and second analyses also detected over 25% of the ATB200 having mono- M6P at the fourth site, corresponding to an average of about 0.3 to about 0.4 mol mono-M6P per mol ATB200 at the fourth site.
  • Fig. 6F shows the N-glycosylation profile of the fifth potential N-glycosylation site, N596.
  • the major N-glycan species are fucosylated di-antennary complex N-glycans.
  • Both the first and second analyses detected over 70% of the ATB200 having a sialic acid residue at the fifth site, corresponding to an average of about 0.8 to about 0.9 mol sialic acid per mol ATB200 at the fifth site.
  • Fig. 6G shows the N-glycosylation profile of the sixth potential N-glycosylation site, N826.
  • the major N-glycan species are di-, tri-, and tetra-antennary complex N-glycans.
  • Both the first and second analyses detected over 80% of the ATB200 having a sialic acid residue at the sixth site, corresponding to an average of about 1.5 to about 1.8 mol sialic acid per mol ATB200 at the sixth site.
  • N-glycosylation at the seventh site, N869 showed approximately 40% N-glycosylation, with the most common N-glycans being A4S3S3GF (12%), A5S3G2F (10%), A4S2G2F (8%) and A6S3G3F (8%).
  • Fig. 6H shows a summary of the phosphorylation at each of the seven potential N- glycosylation sites.
  • both the first and second analyses detected high phosphorylation levels at the first, second, and fourth potential N-glycosylation sites.
  • Both analyses detected over 80% of the ATB200 was mono- or bis-phosphorylated at the first site, over 40% of the ATB200 was mono-phosphorylated at the second site, and over 80% of the ATB200 was mono- or bis-phosphorylated at the fourth site.
  • N-linked glycans from ATB200 were released enzymatically with PNGase-F and labeled with 2-Anthranilic acid (2-AA).
  • the 2-AA labeled N-glycans were further processed by solid phase extraction (SPE) to remove excess salts and other contaminants.
  • SPE solid phase extraction
  • the purified 2-AA N-glycans were dissolved in acetonitrile/water (20/80; v/v), and 10 micrograms were loaded on an amino- polymer analytical column (apHeraTM, Supelco) for High Performance Liquid Chromatography with Fluorescence detection (HPLC-FLD) and High Resolution Mass Spectrometry (HRMS) analysis.
  • the liquid chromatographic (LC) separation was performed under normal phase conditions in a gradient elution mode with mobile phase A (2% acetic acid in acetonitrile) and mobile phase B (5% acetic acid; 20 millimolar ammonium acetate in water adjusted to pH 4.3 with ammonium hydroxide).
  • the initial mobile phase composition was 70% A/30% B.
  • the parameters for the detector RF-20Axs, Shimadzu
  • the HRMS analysis was carried out using a Quadrupole Time of Flight mass spectrometer (Sciex X500B QTOF) operating in Independent Data Acquisition (IDA) mode.
  • the acquired datafiles were converted into mzML files using MSConvert from ProteoWizard, and then GRITS Toolbox 1.2 Morning Blend software (UGA) was utilized for glycan database searching and subsequent annotation of identified N-glycans.
  • the N-glycans were identified using both precursor monoisotopic masses (m/z) and product ion m/z. Experimental product ions and fragmentation patterns were confirmed in-silico using the GlycoWorkbench 2 Application.
  • the ion intensity signal for each N-glycan was“extracted” from the data to create a chromatographic peak called an extracted ion chromatogram (XIC).
  • XIC extracted ion chromatogram
  • the XIC peak created from the ion intensity signal was then integrated and this peak area is a relative quantitative measure of the amount of glycan present. Both the FLD peak areas and mass spectrometer XIC peak areas were used to enable relative quantitation of all the N-linked glycan species of ATB200 reported herein.
  • the ATB200 tested has an average M6P content of 3-5 mol per mol of ATB200 (accounting for both mono-M6P and bis-M6P) and sialic acid content of 4-7 mol per mol of ATB200.
  • the first potential N- glycosylation site of ATB200 has an average M6P content of about 1.4 mol M6P/mol ATB200, accounting for an average mono-M6P content of about 0.25 mol mono-M6P/mol ATB200 and an average bis-M6P content of about 0.56 mol bis-M6P/mol ATB200;
  • the second potential N- glycosylation site of ATB200 has an average M6P content of about 0.5 mol M6P/mol ATB200, with the primary phosphorylated N-glycan species being mono-M6P N-glycans;
  • the third potential N- glycosylation site of ATB200 has an average sialic acid content of about 1 mol sialic acid/mol ATB200;
  • the fourth potential N-glycosylation site of ATB200 has an average M6P content of about 1.4 mol M6P/mol ATB200, accounting for an average mono-
  • an average of about 65% of the N-glycans at the first potential N-glycosylation site of ATB200 are high mannose N-glycans
  • about 89% of the N-glycans at the second potential N-glycosylation site of ATB200 are high mannose N-glycans
  • over half of the N-glycans at the third potential N-glycosylation site of ATB200 are sialylated (with nearly 20% fully sialylated) and about 85% of the N-glycans at the third potential N-glycosylation site of ATB200 are complex N-glycans
  • about 84% of the N-glycans at the fourth potential N-glycosylation site of ATB200 are high mannose N-glycans
  • about 70% of the N- glycans at the fifth potential N-glycosylation site of ATB200 are sialylated (with about 26% fully sialylated
  • ATB200 and Lumizyme® N-glycans were evaluated by MALDI-TOF to determine the individual N-glycan structures found on each ERT.
  • Lumizyme® was obtained from a commercial source. As shown in Fig. 7, ATB200 exhibited four prominent peaks eluting to the right of Lumizyme®. This confirms that ATB200 was phosphorylated to a greater extent than Lumizyme® since this evaluation is by terminal charge rather than CIMPR affinity. As summarized in Fig. 8, ATB200 samples were found to contain lower amounts of non-phosphorylated high-mannose type N- glycans than Lumizyme®.
  • Lumizyme® 73% of the rhGAA in Myozyme® (Fig. 9B) and 78% of the rhGAA in Lumizyme® (Fig. 9A) did not bind to the CIMPR. Indeed, only 27% of the rhGAA in Myozyme® and 22% of the rhGAA in Lumizyme® contained M6P that can be productive to target it to the CIMPR on muscle cells. In contrast, as shown in Fig. 5, under the same condition, more than 70% of the rhGAA in ATB200 was found to bind to the CIMPR.
  • Lumizyme® and ATB200 receptor binding was determined using a CIMPR plate binding assay. Briefly, CIMPR-coated plates were used to capture GAA. Varying concentrations of rhGAA were applied to the immobilized receptor and unbound rhGAA was washed off. The amount of remaining rhGAA was determined by GAA activity. As shown in Fig. 10A, ATB200 bound to CIMPR significantly better than Lumizyme®.
  • Fig. 10B shows the relative content of bis-M6P N-glycans in Lumizyme® (a conventional rhGAA product) and ATB200 according to the invention.
  • Lumizyme® there is on average only 10% of molecules having a bis-phosphorylated N-glycan.
  • every rhGAA molecule in ATB200 has at least one bis-phosphorylated N-glycan.
  • ATB200 was also shown to be efficiently internalized into cells. As depicted in Figs.
  • ATB200 is internalized into both normal and Pompe fibroblast cells and is internalized to a greater degree than the conventional rhGAA product Lumizyme®.
  • ATB200 saturates cellular receptors at about 20 nM, while about 250 nM of Lumizyme® is needed to saturate cellular receptors.
  • the uptake efficiency constant (K up take) extrapolated from these results is 2-3 nm for ATB200 and 56 nM for Lumizyme®, as shown by Fig. 11C.
  • ATB200 and AT2221 were evaluated and compared against those of Alglucosidase alfa in Gaa KO mice.
  • male Gaa KO (3- to 4-month old) and age-matched wild-type (WT) mice were used.
  • Alglucosidase alfa was administered via bolus tail vein intravenous (IV) injection.
  • AT2221 was administered via oral gavage (PO) 30 minutes prior to the IV injection of ATB200. Treatment was given biweekly.
  • Tissue glycogen content in tissues samples was determined using amyloglucosidase digestion, as discussed above. As shown in Fig. 13, a combination of 20 mg/kg ATB200 and 10 mg/kg AT2221 significantly decreased the glycogen content in four different tissues (quadriceps, triceps, gastrocnemius, and heart) as compared to the same dosage of alglucosidase alfa.
  • Tissue samples were also analyzed for biomarker changes following the methods discussed in: Khanna R, et al. (2012),“The pharmacological chaperone AT2220 increases recombinant human acid a-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease,” Plos One 7(7): e40776; and Khanna, R et al. (2014),“The Pharmacological Chaperone AT2220 Increases the Specific Activity and Lysosomal Delivery of Mutant Acid a-Glucosidase, and Promotes Glycogen Reduction in a Transgenic Mouse Model of Pompe Disease,” PLoS ONE 9(7): el02092. As shown in Fig.
  • Dysferlin a protein involved in membrane repair and whose deficiency/mistrafficking is associated with a number of muscular dystrophies. As shown in Fig. 16, dysferlin (brown) was heavily accumulated in the sarcoplasm of Gaa KO mice. Compared to alglucosidase alfa, ATB200 / AT2221 was able to restore dysferlin to the sarcolemma in a greater number of muscle fibers.
  • Example 8 The ATB200-02 Trial: an in-human study of ATB200/AT2221 in patients with Pompe disease
  • Ambulatory patients who have previously received enzyme replacement therapy with alglucosidase alfa are referred to as ambulatory ERT-switch (or ERT-switch ambulatory) patients or Cohort 1 patients.
  • Nonambulatory patients who have previously received enzyme replacement therapy with alglucosidase alfa are referred to as nonambulatory ERT- switch (or ERT-switch nonambulatory) patients or Cohort 2 patients.
  • Ambulatory patients who have not previously received enzyme replacement therapy with alglucosidase alfa are referred to as ERT- naive (or ERT-nafve ambulatory) patients or Cohort 3 patients.
  • Protocols for the 6MWT and FVC test can be found, for example, in Lachman and Schoser, Journal of Rare Diseases, 2013, 8: 160, and in Bittner and Singh, The 6 Minute Walk Test, Cardiology Advisor, 2013.
  • Fig. 19C provides the baseline characteristics for 20 subjects.
  • Safety, tolerability, and biomarkers were assessed for Cohorts 1, 2, and 3 (an updated version of the baseline characteristics for all patients in Cohorts 1-4 is shown in Fig. 44).
  • the following functional assessments were assessed for Cohorts 1 and 3: 6MWT, other motor function tests (time tests and gait-stair-gower-chair (GSGC)), manual muscle test, and pulmonary function (FVC, maximal inspiratory pressure (MIP)/ maximal expiratory pressure (MEP)). Protocols for the time tests and GSGC tests can be found, for example in framan and Schoser, Journal of Rare Diseases, 2013,
  • FIG. 20 A summary of pharmacokinetics data for AT2221 is provided in Fig. 20.
  • Total GAA protein concentrations in plasma for ATB200 at 5 mg/kg, 10 mg/kg, and 20 mg/kg were determined by validated FC-MS/MS quantification of rhGAA-specific“signature” peptide(s) T09 (primary) and T50 (confirmatory) for 11 Cohort 1 patients who completed Stages 1 and 2, as well as for five Cohort 2 patients who completed the PK study in Stage 3.
  • blood samples for plasma total GAA protein concentration were collected prior to the start of ATB200 infusion and at 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, and 24 hour(s) after the start of infusion.
  • blood samples for plasma total GAA protein concentration were collected prior to the start of infusion and at 1, 2, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, and 24 hour(s) after the start of infusion.
  • AT2221 PK analyses were also performed for 11 Cohort 1 patients who completed Stages 1 and 2, as well as for five Cohort 2 patients who completed the PK study in Stage 3. Blood samples for plasma AT2221 concentrations were taken just prior to AT2221 oral administration (time 0) and at 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 11, and 25 hour(s) after AT2221 oral administration. Plasma AT2221 was determined by a validated FC-MS/MS assay.
  • levels of ATB200 increased in a slightly greater-than-dose proportional manner when administered alone.
  • Co-administration of ATB200 at 20 mg/kg with a single high dose (260 mg) of AT2221 increased the total GAA protein exposure area under the curve (AUC) by approximately 17%, compared to ATB200 at 20 mg/kg administered alone (Fig. 21, Fig. 22C).
  • Co-administration of ATB200 at 20 mg/kg with multiple high doses (260 mg) of AT2221 increased the total GAA protein exposure area under the curve (AUC) by approximately 29%, compared to ATB200 at 20 mg/kg administered alone (Fig. 21, Fig. 22D).
  • 6MWT improved for Cohort 1 patients and Cohort 3 patients at month 6 with continued benefit observed to month 12.
  • 6MWT increased in 7/10, 8/10, and 8/8 Cohort 1 patients at months 6, 9, and 12, respectively.
  • 6MWT increased in 5/5, 5/5, and 2/2 Cohort 3 patients at months 6, 9, and 12, respectively.
  • 6MWT increased in 7/10, 9/10, and 8/8 Cohort 1 patients at months 6, 12, and 24, respectively, with one patient not reaching month 24 at the time of this interim analysis.
  • 6MWT increased in 5/5, 5/5, and 5/5 Cohort 3 patients at months 6, 12, and 21, respectively
  • FVC remained stable in Cohort 1 patients over 24 months and increased in Cohort 3 patients over 21 months.
  • FVC was stable or increased in 5/9, 6/9, and 3/7 Cohort 1 patients at months 6, 9, and 12 respectively and FVC was stable or increased in 5/5, 5/5, and 2/2 Cohort 3 patients at months 6, 9, and 12, respectively.
  • FVC was stable or increased in 5/9, 6/9, and 6/7 Cohort 1 patients at months 6, 12, and 24, respectively and FVC was stable or increased in 5/5, 4/5, and 5/5 Cohort 3 patients at months 6, 12, and 21, respectively.
  • maximal inspiratory pressure MIP
  • MEP maximal expiratory pressure
  • R-PAct Rassch-built Pompe -specific activity
  • asch-built Pompe -specific activity is an 18-term questionnaire to measure limitations in activities and social participation in patients with Pompe disease; each activity is ranked from 0 (no) to 2 (yes, without difficulty); total scores range from 0 to 36, with lower scores representing more limitations (van der Beek et al. Neuromuscular Disord. 2013;3:256-64).
  • Fig. 40 patients in Cohorts 1, 2, and 3 showed improvements in R-PAct scores over 21 months (Cohort 2, Cohort 3) or 24 months (Cohort 1).
  • Cohort 1 patients showed an average increase in R-PAct score of 1.5 at six months after treatment compared to baseline, an average increase in R-PAct score of 1.7 at 12 months after treatment compared to baseline, and an average increase in R-PAct score of 1.4 at 24 months after treatment compared to baseline.
  • Cohort 2 patients showed an average increase in R-PAct score of 1.5 at six months after treatment compared to baseline, an average increase in R-PAct score of 1.0 at 12 months after treatment compared to baseline, and an average increase in R-PAct score of 1.5 at 21 months after treatment compared to baseline.
  • Cohort 3 patients showed an average increase in R-PAct score of 2.8 at 12 months after treatment compared to baseline, and an average increase in R-PAct score of 1.8 at 21 months after treatment compared to baseline.
  • the Rotterdam Handicap Scale is a 9-item questionnaire to measure functional ability and level of handicap; each item is ranked from 1 (unable to perform task) to 4 (able to perform task independently); total scores range from 9 to 36; lower scores represent worse functioning (Hagemans et al. Neuromuscular Disord. 2007;17:537-43). As shown in Fig. 40, patients in Cohorts 2 and 3 showed improvements on the Rotterham Handicap Scale over 21 months.
  • Cohort 2 patients showed an average increase in Rotterham Handicap Scale score of 1.5 at six months after treatment compared to baseline, an average increase in Rotterham Handicap Scale score of 0.5 at 12 months after treatment compared to baseline, and an average increase in Rotterham Handicap Scale score of 5.6 at 21 months after treatment compared to baseline.
  • Cohort 3 patients showed an average increase in Rotterham Handicap Scale score of 0.4 at 12 months after treatment compared to baseline and an average increase in Rotterham Handicap Scale score of 0.1 at 21 months after treatment compared to baseline.
  • the Fatigue Severity Scale (“FSS”) is a self-assessment questionnaire consisting of nine questions, each scored on a scale of 1 to 7. The total score ranges from 9 to 63, with higher values representing higher level of fatigue due to the disease condition.
  • the normative value in the healthy population is approximately 21-27 (Grace J et al. Parkinsonism Relat Disord. 2007;13:443- 445).
  • Fig. 28 and Fig. 40 patients in Cohorts 1, 2, and 3 were significantly impacted by fatigue at baseline, and patients in all three cohorts demonstrated an improvement in their FSS after receiving ATB200/AT2221 up to 21 or 24 months.
  • Cohort 1 patients showed an average decrease in FSS score of about 8.0 at 12 months after treatment compared to baseline and an average decrease in FSS score of about 4.4 at 24 months after treatment compared to baseline.
  • Cohort 2 patients showed an average decrease in FSS score of about 12.5 at 12 months after treatment compared to baseline and an average decrease in FSS score of about 15.0 at 21 months after treatment compared to baseline.
  • Cohort 3 patients showed an average decrease in FSS score of about 7.2 at 12 months after treatment compared to baseline and an average decrease in FSS score of about 4.6 at 21 months after treatment compared to baseline.
  • Subject Global Impression of Change is a questionnaire to assess the effects of a drug on eight areas of a patient’s life.
  • Cohort 1 patients reported improvement (e.g.,“somewhat improved”) over 24 months, as did Cohort 2 and Cohort 3 patients (e.g.,“much improved”) over 21 months (Fig. 41).
  • Cohort 1 patients reported an average SGIC score of greater than 4 (e.g., about 4.5 or about 5.0) at six, 12, and/or 24 months after treatment;
  • Cohort 2 patients reported an average SGIC score of greater than 4.5 (e.g., about 5.0, about 5.5) at six, 12, and/or 21 months after treatment;
  • Cohort 3 patients reported an average SGIC score of greater than 4.5 (e.g., about 5.0, about 5.5, about 6.0) at six, 12, and/or 21 months after treatment.
  • CK creatine kinase
  • AFT alanine aminotransferase
  • AST aspartate aminotransferase
  • Urine hexose tetrasaccharide (Hex4) was assessed as a marker of glycogen accumulation. Results for Hex4 available after twelve months of the clinical trial are reported in Fig. 29D and Fig . 42 (data from a maximum of 24 months for Cohort 1 ; data from a maximum of 21 months for Cohorts 2 and 3; lower n values reflect that some data were either unable to be analyzed or were not yet analyzed).
  • IARs infusion-associated reactions
  • the ATB200-02 study was an open-label fixed-sequence, ascending dose, first-in human, phase 1/2 study to evaluate the safety, tolerability, PK, pharmacodynamics (PD), and efficacy of ATB200 co-administered with AT2221 in patients with Pompe disease.
  • Example 14 presents an update to the ATB200-02 study initially summarized in Examples 8-13.
  • Fig. 43 shows an updated ATB200-02 study design, including the dosing information for Cohort 4, which contains six ambulatory ERT switch patents that had been on standard of care ERT for at least seven years prior to switching to AT-GAA after 3-15 months of treatment. In addition, two more patients were enrolled in Cohort 2.
  • Fig. 44 provides updated baseline characteristic for all patients from Cohorts 1-4.
  • 6MWT improved for Cohort 1 patients and Cohort 3 patients at month 6 with continued benefit observed at month 24.
  • 6MWT increased in 7/10, 9/10, and 8/9 Cohort 1 patients at months 6, 12, and 24, respectively.
  • 6MWT increased in 5/5, 5/5, and 5/5 Cohort 3 patients at months 6, 12, and 24, respectively.
  • FVC remained stable in Cohort 1 and Cohort 3 patients.
  • FVC was stable or increased in 5/8 Cohort 1 patients at month 24 and in 5/5 Cohort 3 patients at month 24.
  • maximal inspiratory pressure (MIP) was stable and maximal expiratory pressure (MEP) increased in Cohort 1 patients, while both MIP and MEP increased in Cohort 3 patients.
  • Cohort 1 patients showed an average decrease in FSS score of about 8.0 at month 12 after treatment compared to baseline and an average decrease in FSS score of about 4.1 at month 24 after treatment compared to baseline.
  • Cohort 2 patients showed an average decrease in FSS score of about 12.5 at month 12 after treatment compared to baseline and an average decrease in FSS score of about 13.8 at month 24 after treatment compared to baseline.
  • Fig. 50 shows a clinical assessments summary for patients in Cohort 4.
  • improvements in motor function and strength, as well as pulmonary function as assessed by FVC after 3-15 months of treatment were observed in the majority of the patients.
  • 6MWT increased in 2/5 patients at month 6 and 4/6 patients at last observation carried forward (LOCF) after 3-15 months of treatment.
  • Cohort 4 patients demonstrated a mean +24 meter
  • LOCF includes 1 subject at month 3, 2 subjects at month 6, 2 subjects at month 12, and 1 subject at month 15.
  • Creatine kinase (CK) enzyme was assessed as a marker of muscle damage after the ATB200 treatment.
  • Urine hexose tetrasaccharide (Hex4) was assessed as a marker of glycogen accumulation.
  • ATB200/AT2221 was generally well tolerated over 40+ months of treatment, and there was no impact of immunogenicity on safety, efficacy, and exposure or clearance of ATB200.

Abstract

L'invention concerne des méthodes de traitement de la maladie de Pompe comprenant l'administration d'une population de molécules d'α-glucosidase acide humaine recombinée ou d'une composition pharmaceutique ou d'une formulation associée.
PCT/US2020/016794 2019-02-05 2020-02-05 Alpha-glucosidase acide humaine recombinée et utilisations associées WO2020163480A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962801355P 2019-02-05 2019-02-05
US62/801,355 2019-02-05
US201962908869P 2019-10-01 2019-10-01
US62/908,869 2019-10-01

Publications (1)

Publication Number Publication Date
WO2020163480A1 true WO2020163480A1 (fr) 2020-08-13

Family

ID=71947211

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/016794 WO2020163480A1 (fr) 2019-02-05 2020-02-05 Alpha-glucosidase acide humaine recombinée et utilisations associées

Country Status (1)

Country Link
WO (1) WO2020163480A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021046443A1 (fr) * 2019-09-06 2021-03-11 Amicus Therapeutics, Inc. Procédé de capture et de purification de produits biologiques
WO2023215865A1 (fr) 2022-05-05 2023-11-09 Amicus Therapeutics, Inc. Méthodes de traitement de la maladie de pompe

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8900552B2 (en) * 2000-07-18 2014-12-02 Duke University Treatment of glycogen storage disease type II
US20180228877A1 (en) * 2015-12-30 2018-08-16 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of pompe disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8900552B2 (en) * 2000-07-18 2014-12-02 Duke University Treatment of glycogen storage disease type II
US20180228877A1 (en) * 2015-12-30 2018-08-16 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of pompe disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"NCT03729362 PROPEL Study - A Study Comparing ATB200/ AT 2221 With Alglucosidase/Placeb o in Adult Subjects With LOPD", 3 December 2018 (2018-12-03), pages 1 - 9, XP055729599, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT03729362?V_3=Viewt#StudyPageTop>> [retrieved on 20200428] *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021046443A1 (fr) * 2019-09-06 2021-03-11 Amicus Therapeutics, Inc. Procédé de capture et de purification de produits biologiques
WO2023215865A1 (fr) 2022-05-05 2023-11-09 Amicus Therapeutics, Inc. Méthodes de traitement de la maladie de pompe

Similar Documents

Publication Publication Date Title
EP3624831B1 (fr) Alpha-glucosidase d&#39;acide humain recombinant
US20230079225A1 (en) Method For Selection Of High M6P Recombinant Proteins
WO2020163480A1 (fr) Alpha-glucosidase acide humaine recombinée et utilisations associées
AU2022218792A1 (en) Recombinant human acid alpha-glucosidase and uses thereof
WO2023215865A1 (fr) Méthodes de traitement de la maladie de pompe
EA045409B1 (ru) Рекомбинантная человеческая кислая альфа-глюкозидаза
CN117157095A (zh) 重组人类酸性α-葡萄糖苷酶和其用途
JP2024063015A (ja) 高ｍ６ｐ組換えタンパク質の選択方法
EP3436577A1 (fr) Procédé de sélection de protéines recombinées à teneur élevée en m6p

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20752436

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20752436

Country of ref document: EP

Kind code of ref document: A1